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Abstract
Due to limited treatment options for critical limb ischemia (CLI), cellular-based therapies have been
investigated to induce blood vessel regeneration. Bone marrow-mesenchymal stromal/stem cells (BMMSC) have shown pre-clinical success in animal models of CLI as they possess pro-angiogenic and
immunomodulatory functions. However, clinical translation has been hindered by inadequate expansion
and delivery strategies. This project aimed to characterize the phenotype and pro-angiogenic secretory
function of BM-MSC on decellularized adipose tissue (DAT) bioscaffolds as expansion platforms.
Compared to cells grown on tissue-culture plastic, DAT substrates supported BM-MSC growth,
regenerative marker expression, and pro-angiogenic secretory function. Conditioned media generated by
BM-MSC cultured on DAT coatings were enriched with factors associated with wound healing and
significantly increased human endothelial cell survival under serum-free conditions in vitro. Overall,
these studies show that DAT constructs present a promising tissue engineering approach to expand MSC
while enhancing regenerative potential.

Keywords: Lower Extremity Arterial Disease, Angiogenesis, Cellular-based Therapies, Mesenchymal
Stromal/Stem Cells, Biomaterials, Decellularized Adipose Tissue
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Summary for Lay Audience
Lower Extremity Arterial Disease (LEAD), also known as Peripheral Artery Disease (PAD), is caused by
plaque accumulation in the blood vessels to the limbs, leading to reduced blood supply to the lower limbs.
If the blood supply is reduced enough, patients will develop the most severe form of PAD known as
critical limb ischemia (CLI). Patients with CLI present with resting limb pain, non-healing ulcers, and
gangrene. Unfortunately, due to limited treatment options, many patients may require limb amputation
and face a very high mortality rate. As a result, there has been interest in cellular-based therapies to
regenerate new blood vessels in ischemic limbs. Bone marrow-derived mesenchymal stromal/stem cells
(BM-MSC) are regenerative cells that have demonstrated promising therapeutic results in stimulating
blood vessel formation in animal models of CLI. However, this benefit has not yet been translated
clinically, as challenges with cell expansion and survival after injection have limited clinical progress.
Generating enough cells for clinical use is a challenge as expanded cells lose regenerative abilities. Cell
delivery is also difficult, with poor cell retention and survival after injection into the affected limbs. This
project aimed to improve BM-MSC expansion by investigating alternative culturing methods using
human fat-derived bioscaffolds. Compared to conventional culturing on plastic, fat-derived bioscaffolds
increased the yield of viable BM-MSC and retention of cell markers associated with enhanced
regenerative capacity. Additionally, culturing BM-MSC on fat-derived bioscaffolds enhanced their
secretory abilities and their capacity to promote endothelial cell survival in vitro. Overall, this study
aimed to enhance BM-MSC culture using biomaterials to improve MSC-based CLI therapies.
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Chapter 1.0 Introduction
1.1 Ischemic Cardiovascular Disease
The cardiovascular system plays an integral role in the circulation of blood throughout the body in order
to deliver vital nutrients and oxygen and to remove cellular waste from metabolic activity1. This is
achieved through a complex network of arteries, veins, and capillaries. Lining the walls of blood vessels
is an interconnected system of endothelial cells (EC) that act as a barrier between blood circulation and
tissues1,2. The endothelium serves to regulate vascular tone, blood flow, and platelet function3–5.
Dysfunction of the endothelium is a major contributor to cardiovascular disease (CVD) which refers to
any condition affecting the heart or vascular system3,6. Ischemic CVD are often complications of
atherosclerotic plaque accumulation in the blood vessel walls, which impairs blood flow to target organs7–
9

and leads to myocardial infarction, coronary artery disease, peripheral artery disease, and stroke1,6,7,10.

Collectively, CVD remains the leading cause of death worldwide, claiming 17.9 million lives in 20176,11.
In the last two decades, the incidence of CVD has grown by > 120% and is expected to continue to grow
over the next decade12,13. In addition to high rates of morbidity and mortality, CVD also places a
tremendous economic burden on the health care system, costing $213 billion per year in the United States
alone11,14.

1.2 Blood Vessel Structure and Function
The anatomy of blood vessels generally consists of EC, smooth muscle cells (SMC), pericytes,
fibroblasts, and extracellular matrix (ECM) consisting of elastin, collagen, and glycosaminoglycans3,15.
The vessel wall is comprised of three major layers that can be histologically distinguished in large
vessels16. The outermost layer consists of the tunica adventitia, providing shape and structural integrity
through collagen-rich connective tissue and fibroblasts15. The middle layer is the tunica media, composed
of collagen and smooth muscle tissue, which regulates artery diameter through muscle contractions,
playing a crucial role in regulating blood flow4,16. Lastly, the innermost layer, the tunica intima, consists
of a single-cell endothelial lining that provides a pathway for blood to travel4,15. Within each layer, the
relative composition of muscle and collagen content differ depending on the size and location of the blood
4

vessels. This ensures vessels are suited for unique physiological roles throughout the body. Large blood
vessels such as the aorta contain high elastin content and have relatively low smooth muscle to withstand
the great pressure generated by powerful contractions of the heart1,15. As vessels leave the heart and
bifurcate into smaller arterioles, smooth muscle content increases to allow for spatial control over blood
velocity through inner diameter regulation17. Vessels eventually bifurcate into small capillaries, composed
of a single EC layer attached to a basal lamina1,3. Here nutrients, metabolites, and gases are exchanged to
feed the target tissue and eliminate cellular waste, with the thin walls allowing for efficient diffusion18.
Surrounding the single endothelial cell layers are supportive cells called pericytes, which wrap around
and stabilize the vessels19.

1.2.1 Endothelial Cell Homeostasis
The role of EC in vascular homeostasis was first described in detail by Furchgott & Zawadzki in 198020.
EC are found in all the blood vessels lining the inner tunica intima, and are heavily involved in regulating
blood flow, formation of new blood vessels, and site-specific infiltration of immune cells20,21. In the
arterioles, EC regulate vasomotor tone through complex chemical communication with SMC to regulate
vessel diameter. EC predominantly achieve this through nitric oxide (NO) production and release in
response to chemical or physical cues from the surrounding tissues, inducing local vasorelaxation4,20,22,23.
EC also regulate immune cell infiltration through locally secreted inflammatory cytokines following
tissue injury to initiate repair. EC recruit immune cells by upregulating expression of adhesion molecules,
such as vascular endothelial adhesion molecule-1 (VCAM-1) to bind circulating immune cells and initiate
infiltration into the injured tissue23–25. EC also secrete enzymes to control coagulation following tissue
injury to prevent blood loss3,21,23. Following tissue injury, a chain of pro-inflammatory and regenerative
processes are triggered. First, sub-endothelial collagen fibers are exposed to circulating blood, which
activates EC and promotes adhesion of circulating platelets through von Willebrand Factor (vWF),
initiating the clotting process21,26. Activated EC also express tissue factor (TF), which proteolytically
cleaves a series of inactive coagulation factors to ultimately produce thrombin27. Thrombin activates
adhered platelets to form platelet aggregates, further activating other pro-coagulation factors21,27. Finally,
thrombin also generates insoluble fibrin through a cross-linked fibrin mesh, and together the platelet
aggregates and fibrin networks form a stable clot to prevent blood loss21,23,26.
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1.2.2 Atherosclerosis
Atherosclerosis is the most frequent initiator of CVD, characterized by the accumulation of plaque
consisting of lipids, calcium, and fibrin28. Atherosclerotic plaque also has cellular components consisting
of EC, leukocytes, and SMC28. As the plaque accumulates, it thickens the blood vessel wall, greatly
obstructing blood flow to the target tissue28. Ultimately, atherosclerosis is the result of chronic
inflammation associated with the accumulation of lipid molecules9. Although the direct cause remains
controversial, factors such as elevated plasma cholesterol levels, hypertension, diabetes, smoking, and
physical inactivity are among the greatest risk factors12,29.
Not all arteries are equally susceptible to atherogenesis, and it has been shown that areas with lower
laminar flow are more susceptible30. Due to effects on gene expression, cytoskeletal arrangement,
leukocyte adhesion, and inflammation28,30, an accumulation of these factors leads to EC dysfunction
resulting in low-density lipoprotein (LDL) extravasating through the leaky and defective endothelium in
the tunica intima layer of the artery9,28. Although still controversial, the LDL-oxidation hypothesis has
been under investigation as a major cause for atherogenesis9,28. More specifically, following deposition,
LDL particles interact with subendothelial ECM and are exposed to cell-derived oxidants, forming
oxidized LDL28,31. LDL oxidation is also mediated by resident inflammatory cells31, myeloperoxidase32,
lipoxygenase33, and/or reactive oxygen species (ROS)9. The pro-inflammatory environment also activates
EC28, which recruit circulating leukocytes through upregulation of VCAM-1, E-selectin, and Pselectin9,24. During atherogenesis circulating monocytes are predominantly recruited and to a lesser extent,
T-lymphocytes. Chemotaxis occurs by oxidized LDL and other pro-inflammatory cytokines, which
facilitates leukocyte trans-endothelial migration9. Macrophages will uptake LDL particles through
scavenger receptors and become lipid-filled foam cells and continue to uptake LDL until apoptosis or
necrosis occurs, forming a soft and destabilized lipid-rich atherosclerotic core9,28,34,35.
The inflammatory environment that is filled with apoptotic and necrotic immune cells stimulates SMC
from the tunica media to migrate and proliferate to repair the injury28,36. This initiates a fibroproliferative
response resulting in ECM deposition over the growing plaque to form a fibrous cap, which is susceptible
to rupture34. Atherosclerotic plaque alone can greatly reduce blood flow, however in advanced stages the
plaque can rupture and turn into a thrombus. The thrombotic-rich plaque can enter the circulation and
rapidly coagulate to form an atherothrombotic clot28. The atherothrombotic clot can dislodge downstream

6

in a narrower vessel, causing a complete blockage and depending on the location, can present with a lifethreatening event such as a myocardial infarction or stroke28,29.

1.2.3 Peripheral Artery Disease
Peripheral artery disease (PAD) is characterized by the atherosclerotic narrowing of the arteries, where
plaque accumulation in the extremities results in reduced blood flow to the limbs37. Lower extremity
arterial disease (LEAD) is generally encompassed within the more general term of PAD that can affect
any non-cardiac and non-intracranial arteries. PAD impacts more than 200 million individuals worldwide
and places tremendous morbidity, mortality, and economic burdens on the health care system37. In the
United States alone, it is estimated that PAD costs in excess of $21 billion according to 2016 estimates, a
number that is projected to rise as the population ages37.
Occlusions in LEAD are generally classified into two subtypes: proximal disease, resulting from
obstruction in the aortoiliac and femoropopliteal locations and distal disease, involving the infrapopliteal
location37. During the early stages of LEAD, patients can be asymptomatic. As such, many patients are
underdiagnosed and undertreated, however, when luminal occlusion of the vessel is >50%, patients will
begin reporting intermittent claudication and discomfort38. Hemodynamic analysis of blood flow in the
limbs can be performed to screen for LEAD, by using laser-doppler imaging or ankle-brachial pressure
(ABI) index37. The reduced blood supply creates a shortage of nutrient and oxygen delivery to tissues and
if the occlusion progresses, patients will enter late-stage LEAD, known as critical limb ischemia
(CLI)37,38. The reduced blood supply creates a cascade of pathophysiological events that results in patients
presenting with resting limb pain, non-healing ulcers, and gangrene37–39.
In response to ischemia, EC respond through vasodilation and arteriogenesis, thereby increasing blood
supply through activation of pre-existing arteriole collaterals40. Arterioles eventually reach maximal
vasodilation and become insensitive to pro-vasodilatory stimuli, ultimately failing to supply adequate
blood to the limb37,40,41. Additionally, vessels affected in CLI have decreased wall thickness, decreased
cross-sectional area, and decreased wall-to-lumen ratio, leading to increased fluid extravasation of fluid
and subsequent edema41. The influx of fluid into the interstitial compartments of the limb increases the
hydrostatic pressure, further impairing oxygen and nutrient diffusion to the limb37,41.
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In addition to macrovascular pathologies, microvascular pathologies also develop as the chronic ischemia
leads to EC dysfunction41. Increased ROS production within the EC and surrounding tissues creates a
highly inflammatory environment and results in inappropriate platelet activation, immune cell infiltration,
and unregulated vasomotor control10,21,41. Collectively, these pathological factors lead to microthrombi
formation, effectively impeding oxygen and nutrient exchange at the capillary level39.

1.2.4 Current Therapeutic Approaches for CLI
Following diagnosis, the goal of treatment plans are to relieve ischemic pain, heal ischemic ulcers,
prevent limb amputation, improve patient function and quality-of-life37,38. Revascularization bypass and
endovascular catheterization procedures are employed to restore blood flow and salvage the limb42.
Although these procedures are successful in improving quality-of-life, amputation and mortality rates
remain high for individuals living with CLI37. Further, it is estimated that > 50% of patients do not qualify
for surgical intervention due to diffuse blockages and various comorbidities39. Pharmacological
interventions are also used, mainly to treat cardiovascular risks including medications to treat
hypertension, hyperlipidemia, and diabetes, as well as antiplatelet agents to prevent clotting37. Due to
limited treatment options, amputation is required in approximately 20% of patients and CLI has a
mortality rate of up to 27% at 1-year post-diagnosis43.

1.3 Blood Vessel Regeneration
During physiological development and in various pathologies, the body utilizes complex processes to
generate new blood vessels to various organ systems44. This predominantly occurs through angiogenesis,
vasculogenesis, and arteriogenesis, a series of complex processes that rely on the orchestration of many
cells, chemical, and mechanical cues (Figure. 1.1)45. Angiogenesis and arteriogenesis are the predominant
processes that occur in the adult organism and are in response to mechanical cues or tissue hypoxia to
supply ischemic areas with essential oxygen and nutrients44,45. Oxygen and hemodynamic factors are thus
crucial in regulating blood vessel regeneration. In the past 50 years, therapeutic control of angiogenesis
has gained tremendous interest, as stimulating angiogenesis can be therapeutic in PAD and wound
healing, while inhibiting angiogenesis can be therapeutic in cancer46
8
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Figure 1.1 Overview of mechanisms for blood vessel regeneration. (A) Angiogenesis, the formation of
new blood vessels from pre-existing vessels through sprouting or intussusception17. (B) Vasculogenesis,
the de novo synthesis of new blood vessels from BM-derived endothelial progenitor cells47. (C)
Arteriogenesis, shear stress induces remodelling of already existing collateral vessels that act as an
alternative route for blood flow48. (D) All of these processes occur in concert and are crucial for vascular
repair and regeneration. Figure adopted with permission49.

1.3.1 Angiogenesis
The formation of new blood vessels from pre-existing vessels is termed angiogenesis, a complex multistep process that is mediated by cytokines secreted from vessel-resident EC44. There are two types of
angiogenesis, sprouting and intussusceptive angiogenesis45,46. The latter is also referred to as splitting
angiogenesis, as it involves the formation of an intraluminal tissue pillar inside the vessel followed by
9

splitting into two separate conduits50. Intussusceptive angiogenesis occurs relatively quickly, as it does
not require EC proliferation or migration, only reorganization of existing EC51.
Hypoxia is the major driving force in stimulating sprouting angiogenesis, where cellular oxygen sensing
mechanisms trigger new blood vessel formation to satisfy metabolic demands46. Hypoxia-inducible factor
1-α (HIF1-α) is a master regulator of oxygen homeostasis. Under normoxic conditions, proline residues of
HIF1-α are marked for degradation through hydroxylation by prolyl-4-hydroxylase (PHDs) using oxygen
as a co-factor, leading to ubiquitination and proteasomal degradation of HIF1-α46,52. Under hypoxic
conditions, the activity of PHD is decreased, and HIF1-α translocates into the nucleus to bind HIF1-β.
Together this heteromeric dimer induces the transcription of various proangiogenic factors such as
vascular endothelial growth factor-A (VEGF-A), transforming growth factor-β (TGF-β), erythropoietin
(EPO), platelet-derived growth factor (PDGF), and stromal derived factor-1 (SDF-1)51,52 . Following the
release of proangiogenic cytokines from tissue-resident cells due to hypoxia, factors bind to receptors on
endothelial cells to stimulate angiogenesis46,52. Endothelial tip cells guide the development of the new
capillary towards the angiogenic stimulus such as VEGF-A52,53 (Figure 1.1A).
Sprouting angiogenesis relies on a delicate balance between numerous inhibitory and stimulatory
angiogenic signals such as VEGF/VEGF-receptor (VEGFR) and angiopoietin-1(Ang1) /TIE2 receptor
signalling pathways54. EC are maintained predominantly in a quiescent state, however, when a vessel
senses a pro-angiogenic signal such as VEGF, Ang2, or fibroblast growth factor (FGF), a series of events
occur to sprout a new blood vessel46. First, the permeability of the vessel is increased through VEGF
activity45, and a single EC becomes the tip cell to allow for coordinated migration towards a proangiogenic signal46,55. Lagging behind the tip cell are stalk cells, which divide to elongate the stock and
will later form the lumen of the new vessel51,55.
Thin cellular processes on the tip cells secrete proteolytic enzymes such as matrix metalloproteinases
(MMPs), digesting a pathway through the ECM for the sprouting vessel46,56. Tip cells also possess
filopodia to sense the surrounding environment and guide the elongating stalk46,51. The ECM provides
critical structural and cell-instructive roles throughout the angiogenic process, and requires a balance
between formation and degradation for physiological angiogenesis to occur56. To ensure matrix
degradation is balanced, activated EC also secrete tissue inhibitors of matrix metalloproteinases (TIMPs)
that inhibit MMPs46. An inner lumen forms through vacuole formation and coalescence within a series of
stalk cells51. Maturation and stabilization of the new blood vessel are then achieved by the recruitment of
pericytes to wrap around the blood vessel, as well as the deposition of ECM and resumed EC quiescent
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state46,51. Notably, processes of this angiogenic cascade are also supported by cytokines and growth
factors secreted by circulating myeloid progenitor cells and monocytes (collectively referred to as
circulating angiogenic cells or CAC) and by matrix remodelling activities by polarized tissue
macrophages.

1.3.2 Vasculogenesis
Vasculogenesis predominantly occurs in the developing fetus and is defined as the de novo synthesis of
blood vessels from endothelial precursor / progenitor cells (EPC)47,57. In the embryonic yolk sac,
vasculogenesis occurs in multiple blood islands in the mesodermal layer, mediated primarily by highly
proliferative EPC. During embryonic development, EPC undergo coalescence to form major embryonic
vessels from cords of adherent EC that become endothelial tubes through morphogenesis and form a
vascular plexus57,58.
It was first believed that vasculogenesis only occurred during embryonic development, however in 1997
Asahara isolated EPC from human bone marrow, using the hematopoietic marker CD34 and endothelial
marker VEGFR259. These markers are also expressed on hematopoietic stem and progenitor cells , as
endothelial and hematopoietic precursors share a common progenitor during development59.
Transplantation of CD34+/VEGFR2+ blood cells in immunodeficient mice with surgically-induced limb
ischemia resulted in incorporation of the injected cells in new blood vessels, providing possible evidence
of vasculogenesis59. Since then, a growing body of evidence has been investigating the occurrence of
post-natal vasculogenesis in blood vessel maintenance (Figure 1.1B) which still remains controversial,
and maybe stimulated by VEGF, granulocyte colony-stimulating factor (G-CSF), Ang-1, and SDF57,60–63.

1.3.3

Arteriogenesis

Angiogenesis is primarily driven by hypoxia resulting from reduced blood supply or increased metabolic
demand. In contrast, arteriogenesis is triggered by physical fluid and shear-stress forces17,48.
Arteriogenesis is defined as the remodelling of pre-existing arterioles in fully developed blood vessels, or
the growth of new collaterals in response to physical cues48. Redundancies in the vasculature exist, as
collateral vessels with low blood flow supplying the same tissue can be activated to increase flow if
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primary vessels become obstructed48. Blood is redirected through the collaterals from neighbouring
vessels, and perfusion through the collateral arterioles induces a series of physiological changes to
accommodate new blood supply.
As blood velocity increases through the vessel, it induces longitudinal shear stress sensed by EC48,64. This
results in altered gene expression, primarily increasing the synthesis and release of NO, leading to
vasodilation and subsequently increased blood flow64. Shear stress also induces the stimulation of
VEGFR and further activates EC, leading to upregulation of monocyte chemoattractant protein-1 (MCP1) and intracellular adhesion molecule-1 (ICAM-1), essential factors for the recruitment of monocytes48,64.
Infiltrating monocytes release a variety of growth factors such as FGF, tumor necrosis factor alpha (TNFα), and other chemokines that will induce matrix remodelling and the proliferation and migration of
EC48,64,65. PDGF is also secreted by monocytes to promote SMC proliferation and pericyte stabilization of
collateral vessels64. Collectively, this chain of events leads to the remodelling of the collateral vessel to
become highly conductive and efficiently perfuse blood and nutrients to the ischemic area64 (Figure
1.1C).

1.4 Cellular Therapies to Induce Vascular Regeneration
Due to limited treatment options for CLI, cellular-based therapies have been under intense investigation
for the past few decades, focused on promoting angiogenesis and revascularization in patients with
CVD49,66. To date, over 50 phase I/II clinical trials have investigated the therapeutic potential of a variety
of cellular-based therapies to treat patients with PAD49. Most commonly, trials involved direct injection
of bone marrow or peripheral blood-derived mononuclear cells (MNC), a heterogenous cell population of
primarily mature cell types of the hematopoietic, endothelial, and mesenchymal lineages that support
angiogenesis49. Although early clinical trials with autologous cells did not significantly reduce amputation
rates, trials injecting unpurified autologous peripheral blood-MNC (PB-MNC) in CLI patients showed
consistent improvements in ABI scores, pain-free walking time, wound healing, and ulcer healing
compared to placebo67–69.
Mesenchymal stromal/stem cells (MSC) are also under heavy investigation in cell therapies for CLI due
to their pro-angiogenic, immunomodulatory, and differentiative potential into mural and perivascular
cells70. Allogenic transplantation of BM-MSC increased ABI at 6 months compared to placebo71, further
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when injected into the ischemic hind limb of rats, BM-MSC induced greater perfusion and capillary
density increase than BM-MNC49,72. A trial involving 41 CLI patients comparing BM-MSC and BMMNC transplantation showed that the BM-MSC cohort had greater ulcer healing rates, limb perfusion,
pain-free walking times, and ABI73. Thus, MSC represent a promising therapeutic cell source to treat
patients with CLI. However, the field has yet to see a successful phase III trial. As such, further research
is still being conducted to utilize the pro-angiogenic potential of BM-MSC and push the use of cellular
based therapies a step closer to mainstream clinical use.

1.4.1 Mesenchymal Stromal/stem Cells
In 1974 Alexander Freidenstein isolated murine bone marrow cells that were distinct from hematopoietic
stem cells (HSC)74. Freidenstein termed these cells colony forming units of fibroblasts (CFU-F),
characterized as plastic adherent cells with clonogenic potential that were inherently osteogenic75.
Subsequently, numerous contributions showed CFU-F also possessed adipogenic and chondrogenic
differentiative capacities in culture and the population was subsequently termed multipotent stromal cells
or MSC76,77. This supported Arnold Caplan’s theory of the existence of a mesenchymal stem cell (also
MSC) in the bone marrow78, highlighting CFU-F’s mesenchymal origin and their vast therapeutic
potential79. However, the use of the term “stem cell” to describe these cells has long been debated as
direct evidence of self-renewal remains controversial. As such, the nomenclature “mesenchymal
stromal/stem cells” is now often used to describe this cell population80.
MSC reside in the connective tissues of most organs, and many labs have isolated MSC or MSC-like cells
from various tissues including skeletal muscle, adipose tissue, umbilical cord, pancreas, blood vessels,
dental pulp, liver, and lung81–86. However, heterogeneity exists in cell surface marker expression and
differentiative capacity between these MSC populations. Additionally, there has been great debate over
the appropriate purifying techniques from different sources79. Hence, the International Society of Cell &
Gene Therapy (ISCT) set the following three minimal defining criteria to characterize MSC: 1) tri-lineage
differentiative abilities into fat, bone, and cartilage in culture; (2) plastic adherence, and (3) exhibit >95%
cell surface expression of the stromal markers CD73, CD90, and CD105 while lacking the expression of
the hematopoietic markers CD45, CD14, CD11b, CD19 and human leukocyte antigen (HLA) isotype DR
in ≤ 2% of cells79,87.
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In addition to their phenotypic and differentiative traits, MSC also possess great regenerative potential to
repair tissue damage in response to injury through the production and secretion of immunomodulatory
and pro-angiogenic factors (Figure. 1.2)70,79,88. These therapeutic benefits have been translated in
preclinical models for various diseases including osteogenesis imperfecta, lung injury, kidney disease,
diabetes, graft-vs-host disease, myocardial infarction, and neurological disorders79,89–91. It is thought that
MSC exert this therapeutic benefit primarily through paracrine means79, noted because in clinical and preclinical trials a significant improvement was observed despite extremely low and transient engraftment 77.

1.4.2 Therapeutic Potential of MSC
MSC are regenerative cells that preferentially home to areas of injury and initiate regenerative processes
through the secretion of a variety of growth factors and cytokines70,79,90,91. Nagaya et al., showed that
intravenously administered MSC homed to infarcted myocardium in ischemic heart models in mice and
improved cardiac function following acute myocardial infarction by enhancing angiogenesis and
myogenesis92. This therapeutic benefit was not due to MSC differentiative potential, but rather their
paracrine activity92,93. Several studies have shown that MSC secrete a variety of factors that are
immunomodulatory, antiapoptotic, and pro-angiogenic70,88,94,95. MSC-conditioned media (CdM) promoted
endothelial cell tubule formation, survival and proliferation in vitro, with proteomic analysis showing the
presence of pro-angiogenic cytokines VEGF, hepatocyte growth factor (HGF), MCP-1, interleukin 6 (IL6), TGF-β1, insulin-like growth factor-1 (IGF-1), epidermal growth factor (EGF-1), SDF-1, and Ang-1,
that were secreted depending on the culture conditions70,79,92,94–96. Additionally, injected MSC CdM
increased blood vessel formation and promoted blood flow in mice with surgically induced limbischemia96. MSC CdM also increased endothelial cell migration and survival94,97, and improved EC
growth and EPC recruitment to the ischemic limb in CLI-mouse models95,96.
MSC also exert a therapeutic effect through the production of membrane-enveloped exosomes involved in
the induction of tissue regeneration and angiogenesis98. Exosomes are extracellular vesicles,
approximately 30-100 nm in diameter that contain genetic material and other bioactive factors including
proteins, RNA and lipid molecules99. MicroRNA (miR), which regulate gene expression at the posttranscriptional level by binding to specific mRNA and inducing degradation or translational inhibition,
are also found in exosomes. MiR are crucial to regulate various cellular physiologies such as cell cycle
progression, hematopoiesis, cancer, and aging100. MSC have been found to secrete a wide array of pro14

angiogenic miRs, such as miR-30b, miR-30c, miR-424, and let-7f. Notably, MSC were able to transfer
miR through exosomes to human umbilical vein endothelial cells (HUVEC), resulting in increased tubule
formation, suggesting a role of miR secretion by MSC within exosomes to support angiogenesis98,100–102.
In addition to pro-angiogenic properties, MSC also attenuate inflammation, a delicate process that must
be regulated during wound healing and angiogenesis103,104. The addition of MSC to an inflammatory
environment induces the secretion of various immunomodulatory cytokines such as prostaglandin E2
(PGE-2), indoleamine 2,3-dioxygenase (IDO), NO, IL-6, HGF and TGF-β105–107. These effectors are
involved in a myriad of complex reciprocal signalling with various inflammatory cells, leading to the
formation of immunoregulatory T cells108, conversion of pro-inflammatory M1 macrophages to
regenerative M2 macrophages88, and downregulation of natural killer cell activity105. In vitro, MSC
supress mixed lymphocyte reactions and are a key regulator of adaptive immune responses, modulating
lymphocyte proliferation and apoptosis108,109. MSC also prevented graft rejection in a baboon skin
allograft model and have mediated immunosuppression in several mouse models109. In 2012, Health
Canada approved the use of MSC in the treatment of graft-vs-host disease, utilizing their potent
immunomodulatory properties110. It is the immunosuppressive qualities of MSC that make them a
promising therapeutic cell source to treat inflammatory diseases such as atherosclerosis, diabetes, critical
limb ischemia, allergy, asthma, and hepatitis103,104,109.
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Cartilage

Figure. 1.2 Overview summary of bone marrow mesenchymal stromal/stem cell properties. MSC
can be obtained from the bone marrow, and are characterized according to three minimal defining criteria;
(1) plastic adherence, (2) cell surface marker expression, and (3) multipotent differentiative capacity into
fat, bone, and cartilage87. In addition to these properties, MSC secrete a wide array of pro-angiogenic and
immunomodulatory cytokines and miRNAs involved in blood vessel formation and the inhibition of
excessive inflammation79. Figure generated using Biorender.
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1.4.3 Current Limitations of Cellular-based Therapies for Ischemic CVD
Although preclinical progress has yielded promising results, challenges associated with MSC expansion
and delivery have hindered clinical translation49. Notably, the survival of MSC after direct injection into
the ischemic limb is transient72, and cell delivery is complicated by detachment-induced apoptosis
initiated upon detaching cells from plastic prior to transplantation111. Additionally, the requirement to
generate many cells with preserved pro-angiogenic function has posed a challenge. It is estimated that
billions of cells will be required for therapeutic purposes in humans, a critical challenge, as MSC lose
desired characteristics such as pro-angiogenic secretory potential and differentiative properties through
extensive proliferation49,111,112. After 4 passages (20-30 generations), more than half of the cells have been
reported to stop proliferating and their differentiative capacity is diminished113,114. For clinical
applications, expansion presents a critical challenge as generating enough cells leads to a significant
frequency of cells that no longer possess the required proliferative and differentiative phenotype115.
Furthermore, BM-MSC from different donors exhibit tissue-specific molecular and functional
heterogeneity, leading to varying levels of immunomodulatory and pro-angiogenic affects49,113.
Conventionally, BM-MSC are cultured on rigid tissue-culture plastics (TCP). Notably, this simplified 2-D
culture of BM-MSC does not recapitulate the complex biochemical and biomechanical properties of the
native ECM-rich environment, resulting in unwanted cell differentiation and loss of secretory function
during expansion49,113–116. The presence of an ECM-rich environment exerts an effect on MSC through a
variety of cell surface receptors. Thus, ECM-derived scaffolds can provide cell-instructive cues to
modulate MSC proliferation, differentiation, and regenerative capacity115,117,118. Lastly, BM-MSC are
typically cultured under static culturing conditions, which lack mechanical stimulation that can provide
important cues that can direct cell phenotype and function through mechano-transduction119. Combining
ECM scaffolds with three-dimensional (3D) dynamic culturing platforms, such as the use of spinner flask
bioreactors, may provide an alternative platform to expand and deliver BM-MSC and harness their
therapeutic potential120.

1.5 The Extracellular Matrix
The ECM is composed of a wide variety of macromolecules that form organized structures to support cell
homeostasis115,121. Beyond structural support as physical scaffolds, the ECM also provides crucial
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biochemical and biomechanical cues that regulate cell growth, migration, differentiation, survival, and
morphogenesis121–123. Fundamentally, the ECM consists of water, proteins, and polysaccharides, however
the exact components are tissue-specific, as each niche has a unique composition and structural
organization124. During tissue development, crosstalk exists between cellular and ECM components that
guide the unique remodelling of a tissue-specific ECM122–124. Through physical and compositional
characteristics, the ECM generates unique structural and biochemical properties in each organ, such as
tensile and compressive strength, elasticity, and water retention124. Additionally, ECM composition is
governed by dynamic processes that can vary greatly not only between different tissues, but between
physiological and pathological states in response to cellular cues124,125. Lastly, the ECM acts as a reservoir
for a variety of latent growth factors, cytokines, and chemokines that are sequestered through specific
ECM binding, and are liberated at physiologically and pathologically relevant times121,124,125.
Cells interact with the ECM through a series of cell surface receptors. More specifically, cell adhesion is
mediated by integrins, discoidin domain receptors (DDRs) and syndecans126. Binding of integrins to the
ECM initiates a bi-directional mechano-transduction signal that regulates gene expression and induces a
variety of signalling molecules to reorganize the cell cytoskeleton and activate various intracellular
pathways127,128. A myriad of signalling pathways can be initiated depending on the integrin heterodimer
bound, and the exact ECM composition126,128.

1.5.1 ECM Composition and Structure
The ECM is predominantly composed of collagen, elastin, glycoproteins, and
proteoglycans/glycosaminoglycans, each serving unique structural and/or functional roles122. Broadly,
ECM components can be divided into structural components consisting of collagen and elastin124,129 and
non-structural components consisting of fibronectin, laminins, and other glycoproteins124,130. The most
abundant protein in the ECM is collagen, a family of fibrous proteins that provide structural support to
tissues. To date, 28 different types of collagen have been characterized123,124,131. Fibrous collagens include
collagen types I, II, III, V, and XI, while collagen type IV is classified as a network type or sheet-like
forming collagen123. Fibrous collagens impart stiffness and tensile strength to connective tissues to
withstand tension, shear, and pressure forces123,132. Collagen also possesses a functional role in the ECM
and guides adhesion, proliferation, migration, and tissue development through integrin singalling124,133.
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Elastin can be combined with collagen to provide tissue elasticity and is predominantly composed of
tropoelastin subunits cross-linked to an outer layer of microfibrils124,134.
Fibronectin is another fibrous protein that is involved in directing cell attachment through pleotropic
effects and functions as a mechano-regulator of cell behaviour and wound healing124,135. Laminins, are
glycoproteins involved in mediating multiple cell functions including migration and differentiation
through their target integrin receptor binding122,136.
Proteoglycans are another crucial component of the ECM and consist of a core protein covalently
attached to one or more glycosaminoglycan (GAG) chains, which play a major role in water retention
122,124

. GAGs and proteoglycans bind a variety of growth factors, which establishes cytokine gradients in

the ECM that play vital roles during tissue development121. GAGs are also directly cell-instructive,
playing a role in cell survival, proliferation, and migration124,127. The bioactivity of GAGs is achieved
directly through intra-cellular signalling pathways, or indirectly by sequestered cytokines and growth
factors that are released following ECM degradation127,137.
Collectively, the complex composition of the ECM allows for a cell-instructive niche to support cell
homeostasis and initiate appropriate responses to various pathologies and tissue injury122–124,126. Hence,
the use of ECM to guide and support cell growth presents as an alternative expansion platform to direct
cell behaviour using 3D engineered biomaterials138.

1.5.2 The Effects of ECM on MSC
MSC possess a variety of cell surface receptors that allow for cell adhesion and interactions with the
ECM, sensing structural and biochemical cues, which regulate proliferation and guide lineage-specific
differentiation115. The composition, mechanical properties, and surface topography of the ECM elicit a
variety of responses in MSC115,139. For example, MSC express tissue-specific transcription factors when
cultured on substrates mimicking the elastic properties of different organs139,140, and when cultured on soft
substrates MSC better maintained multipotency compared to culture on stiff substrates141. Additionally,
ECM stiffness can direct lineage-specific differentiation, where soft substrates promote cell rounding
which favours adipogenic differentiation, and stiff substrates promote elongation, favouring osteogenic
differentiation140,142,143. ECM stiffness and composition also affect MSC pro-angiogenic and
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immunomodulatory properties, where culture on softer substrates enhanced the secretory potential of
MSC in stimulating EC tubulogenesis144,145.
MSC also secrete their own ECM, and recent interest has developed in obtaining ECM-derived from
MSC for biomaterial applications115. Culture on ECM derived from MSC improved MSC proliferation,
differentiative abilities, and reduced cellular senescence compared to culture on TCP or matrigel 115,146,147.
Compositional differences have also been observed between ECM produced by early and late passage
MSC. Further, ECM produced by early MSC was able to rejuvenate properties of highly-expanded, latepassage MSC115,119,148. Finally, various components of the ECM when used alone can guide MSC
behaviour. Tropoelastin, an ECM structural component, has been shown to improve human MSC
expansion through integrin signalling and may reduce the need for serum requirements in culture140,149,150.
Overall, these bioactive effects illuminate the complex role of the ECM in guiding and maintaining the
growth, proliferation, and therapeutic potential of MSC, and warrants the investigation of utilizing ECM
to enhance the pro-angiogenic potential of MSC in this thesis.

1.5.3 Decellularized Tissue as an ECM Source
To produce an ECM-like environment, decellularized materials that retain native chemical and
mechanical composition have garnered tremendous attention in the past few decades151. To develop
decellularized scaffolds for culture and delivery, tissues can be obtained and decellularized to remove
cellular and immunogenic components, while the structural and functional proteins are minimally
disrupted152. There are many methods for decellularization including physical, chemical, and enzymatic
processes. Physical treatments use sonication, agitation, and/or freeze/thawing cycles to release cellular
content153. Chemical treatments rely on detergents, organic solvents, chelating agents, and/or ionic
solutions to disrupt cell membranes152,153. Finally, enzymatic treatments utilize proteolytic enzymes to
degrade proteins and nucleases to digest nucleotide bonds152. Various methods are often combined to
generate tissue-specific protocols to ensure efficient decellularization while conserving the native ECM
structure and biochemical composition as much as possible152,154. Decellularized scaffolds have been
fabricated from a variety of tissue sources including heart155, blood vessels156, lung157, skin158, nerve159,
cornea160, liver161, kidney162, and fat163, which have been investigated for various tissue engineering and
regenerative medicine applications154.
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Decellularized scaffolds provide cell-ECM interactions that stimulate intracellular signalling pathways to
regulate cell survival, proliferation, and differentiation115,118,140. Hence, decellularized scaffolds are
promising biomaterials to enhance the survival and pro-angiogenic capacity of MSC. Further,
decellularized scaffolds may be safe for clinical use since immunogenic components are removed, and
ECM constituents are minimally immunogenic as they are generally conserved amongst species152,164,165.
Although xenogeneic implants are well tolerated, it is not preferred due to various complications that can
arise from xenogeneic rejections from residual cellular contamination154. As such, clinical applications
should preferably use abundantly available human tissue sources that are rich in ECM and can be
decellularized for tissue engineering applications.

1.5.4 Decellularized Adipose Tissue
Adipose tissue is abundantly found throughout the body and serves many essential roles in physiological
homeostasis166. Beyond its energy storage roles, adipose tissue is a highly active metabolic and endocrine
organ and serves an important role in providing body heat insulation and a protective cushioning for
organs166,167. In addition to adipocytes that store energy in the form of triglycerides, many different cells
exist in the complex niche of adipose tissue including stromal, nerve, vascular and immune cells167,168.
These cells are anchored by an ECM-rich environment169,170 and the porous cell-instructive nature of the
ECM allows for adipose tissue to be highly vascularized to support complex metabolic and endocrine
roles171,172.
The ECM within adipose tissue is rich in collagen types I – VI, and also contains fibronectin, laminins,
proteoglycans, and GAGs163,170,172,173. Further, it is readily available from routinely discarded waste during
liporeduction surgeries, allowing sufficient quantities to be obtained with relative ease for research and
clinical applications163. Hence, decellularized adipose tissue (DAT) represents a promising biomaterial to
fabricate ECM-rich scaffolds to support cell expansion and delivery.
In 2010, the Flynn lab developed a protocol for fabricating DAT scaffolds as a biomaterial for soft tissue
engineering strategies, which utilizes a detergent-free protocol of chemical, enzymatic, and physical
processing to remove cellular components while retaining native ECM composition163.The use of DAT
for a variety of applications including soft tissue and vascular regeneration have since been investigated.
For soft tissue regeneration, when seeded with adipose-derived stromal cells (ASC), DAT provided an
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adipogenic-instructive microenvironment in vitro and induced pro-angiogenic responses in vivo174.
Further, DAT implants stimulated an adipogenic and angiogenic response by inducing a more proregenerative macrophage phenotype175. Overall, DAT scaffolds were well tolerated and integrated well
with the host tissues and provided a promising platform for accelerating wound healing138,174,175.
Additionally, the Flynn lab has developed various protocols to fabricate many different DAT bioscaffold
formats including coatings, foams, and microcarriers, each suited for unique tissue regeneration
applications163,175–177. A recent collaboration with the Hess lab showed that DAT foams seeded with
human hematopoietic progenitor cells (HPC) increased cell retention, recovery of limb perfusion, and
improved functional limb use in the ischemic limb of CLI-mouse models in comparison to saline
controls178. Microcarriers are also of specific interest as a cell expansion platform, as they can be utilized
within stirred bioreactor systems to achieve dynamic culturing conditions, and could also potentially be
applied as an injectable delivery vehicle120.

1.5.5 Effects of Dynamic Culture on MSC Expansion and Differentiation
Cellular-based therapies have faced challenges in achieving scalable, robust, and cost-effective processes
to generate clinically-applicable cell numbers without the loss of therapeutic potential112,113,179.
Microcarrier technology presents an alternative culturing method involving spherical microcarriers that
can be suspended in growth medium to enable cell adherence under dynamic conditions180. Since initial
characterization in 1967 by Van Wezel181, a variety of microcarriers have been fabricated with differing
size, porosity, composition, and surface modifications tailored to unique ex vivo applications180.
Dynamic culture can be achieved by suspending microcarriers in variety of reactors including rotating
wall microgravity bioreactors182, fluidized-bed bioreactors183, and stirred-tank bioreactors120,176. The
stirred bioreactor utilizes a spinning impeller to generate dynamic culture and allows for fine tuning of
various parameters including pH, stirring rate, and oxygen tension184. Ultimately, microcarrier culturing
strategies allow for efficient scale-up of cell production as they provide a high surface area : volume ratio,
mechanical stimulation for cells, and can be fabricated out of various materials to provide a cellinstructive tissue engineering approach180,181.
By electrospraying α-amylase digested DAT into liquid nitrogen, the Flynn lab generated DAT
microcarriers comprised exclusively of ECM that were approximately 450 µm in diameter and are soft,
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compliant, and highly porous120,138,163. When seeded on DAT microcarriers under dynamic conditions,
ASC showed enhanced proliferation and tri-lineage differentiative capacity compared to cells cultured on
commercially available Cultispher-S microcarriers120. Dynamic culture of MSC has been previously noted
to enhance proliferation compared to conventional methods on TCP, and produced greater cell yields
while reducing the need for enzymatic passaging185,186. Further effects on lineage-specific differentiation
have been observed under different dynamic conditions, as varying shear stress may direct cell
differentiation towards osteogenic or chondrogenic lineages187–189. Further, dynamic culture also affects
MSC paracrine activity. More specifically, CdM generated by human ASC cultured under dynamic
conditions contained higher concentrations of VEGF, bFGF, and HGF and promoted faster wound
healing in athymic mice, compared to CdM generated from static culture on TCP190. Shear stress induced
by dynamic conditions is thought to be one of the major factors stimulating MSC behaviour under
dynamic culture, effectively altering MSC growth and differentiation, depending on the stirring rate
used189. Overall, utilizing dynamic culture maybe a promising way to modulate the expansion,
differentiation, and pro-angiogenic potential of MSC.

1.6 Project Overview
MSC serve as a promising therapeutic cell-based treatment for CLI as they secrete soluble factors that are
immunomodulatory and pro-angiogenic. In preclinical studies, injection of BM-MSC into the ischemic
limbs of mice with surgically induced CLI resulted in increased capillary density and improved limb
perfusion. However, challenges associated with cell expansion, unwanted differentiation and sub-optimal
delivery have hindered clinical translation. First, the requirement to generate many cells with preserved
pro-angiogenic function has posed a challenge, as prolonged expansion can result in the loss of proangiogenic secretory function. Second, the survival of MSC after direct injection into the ischemic limb is
transient, and cell delivery is complicated by detachment-induced apoptosis initiated upon preparing cells
for transplantation. Utilizing the cell-instructive properties of ECM and the supportive properties of
dynamic culture with microcarrier technology, the purpose of this project was to characterize the growth,
cell phenotype, and pro-angiogenic secretory function of BM-MSC cultured on DAT substrates under
dynamic and static conditions.
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1.7 Hypothesis and Specific Aims
Based on the cell-supportive properties of DAT, it was hypothesized that BM-MSC cultured on DAT
bioscaffolds would show enhanced growth, expression of MSC biomarkers, and pro-angiogenic secretory
capacity compared to cells cultured on tissue culture plastic.
To address this hypothesis, the following specific aims were proposed:
AIM 1. Characterize the viability and phenotype of BM-MSC cultured on DAT coatings and
microcarriers in comparison to cells expanded on TCP.
AIM 2. Assess the in vitro pro-angiogenic secretory function of BM-MSC cultured on DAT
substrates in comparison to TCP cultured cells.
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Chapter 2.0 Methods
2.1 DAT Scaffold Fabrication
2.1.1 Adipose Tissue Decellularization
Subcutaneous human adipose tissue was acquired with informed consent from patients undergoing
elective breast reduction or abdominoplasty surgery from various clinics in the London area (University
Hospital, Advanced Medical Group, St. Joseph Hospital, or Victoria Hospital, London, ON). Human
Research Ethics Board approval was obtained from Western University (HREB #105426). Through a
process previously optimized by the Flynn lab, adipose tissue was decellularized using a 5-day detergentfree protocol (Figure. 2.1)163.
Briefly, tissue was excised into ~3 cm3 blocks to maximize surface area and placed in a hypotonic
solution containing 10 mM Tris base and 5 mM EDTA in dH2O (pH 8.0) supplemented with 1%
antibiotic-antimycotic solution (Gibco, Invitrogen, Carlsbad, CA, ABAM) and 0.07% phenylmethanesulphonylfluoride (PMSF) (all steps included ABAM and PMSF supplementation, with exclusion
of PMSF during enzymatic digestion). All agitation was performed at 37 ⁰C on an orbital shaker at 100
rpm. To initiate cell lysis, samples underwent 3 freeze-thaw cycles from - 80 ℃ to 37 ℃, with agitation
during thawing and solution replacement after each thaw cycle. The tissue was then enzymatically
digested with 0.25 % Trypsin-EDTA (Life Technologies, Carlsbad, CA) overnight under agitation. To
remove lipid content, the tissue underwent polar solvent extraction in absolute isopropanol for 48 h, with
solution changes twice daily. The samples were then rinsed in a rinsing buffer comprised of dH2O with
137 mM NaCl, 2.68 mM KCl, 7 mM Na2PO4, and 1.47 mM KH2PO4. The tissue was then digested again
for 6 h in 0.25 % Trypsin-EDTA and rinsed 3 times in rinsing buffer. To remove residual lipids and
genetic material, the tissue was then incubated overnight in a digestion buffer comprised of 55 mM
Na2PO4, 17 mM KH2PO4, 4.9 mM MgSO4·7 H2O, 15 000 U DNase Type II (from bovine pancreas),
12.5 mg RNase Type III A (from bovine pancreas), and 2000 U Lipase Type VI-S (from bovine
pancreas). The tissue was rinsed 3 times in rinsing buffer and subjected to a final extraction in absolute
isopropanol for 8 h.
At the end of processing, the DAT was rinsed 3 times in the rinsing buffer followed by dH2O, transferred
into 50 mL conical tubes, and frozen in -80℃. The DAT was lyophilized for 48 hours, and then minced
with scissors into roughly 0.5 mm2 fragments. Minced DAT was then placed in a milling chamber with
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two 10-mm stainless steel milling balls and cryo-milled in a Retsch Mixer Mill 400 (Retsch, Haan,
Germany). The chamber was submerged in liquid nitrogen for 3 minutes and milled for 3 minutes at 30
Hz. This was repeated for a total of three milling cycles until a fine powder was achieved. Cryomilled
DAT (1 g) was collected in 50 mL conical tubes, weighed, and resuspended in 70% ethanol to
decontaminate it prior to cell culture. Resuspended DAT was placed under agitation at room temperature
(RT) overnight.
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Figure 2.1 Overview of the decellularization and processing of fat tissue. (A) Excised human adipose
tissue. (B) Tissue following freeze/thaw cycles, enzymatic digestion, and first polar extraction, and after
(C) numerous polar extractions and mechanical pressing. (D) Decellularized adipose tissue (DAT)
hydrated in PBS. (E) Lyophilized, and (F) minced lyophilized DAT. (G) Cryo-milled DAT. Scale bars
represent 1 cm. Figure adopted with permission from177.
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2.1.2 DAT Suspension and Coating Fabrication
DAT suspension fabrication was performed following previously established methods in the Flynn lab163.
The decontaminated DAT powder was centrifuged at 1500 x g for 10 minutes and the ethanol in the
supernatant was removed and discarded. The samples were then resuspended in PBS to wash out residual
ethanol and centrifuged at 1500 x g for 10 minutes, which was repeated for a total of three washes. The
1 g of milled DAT powder was digested in 40 mL of 0.22 mM NaH2PO4 solution (pH 5.4) containing 10
mg of α-amylase (1% w/w of DAT powder) for 72 hours under agitation at RT. The samples were then
centrifuged at 1500 x g for 10 minutes, and the supernatant was discarded. The samples were washed by
resuspending in 40 mL of 5% NaCl (w/v) under agitation for 10 minutes and centrifuged at 1500 x g for
10 minutes. The supernatant was discarded, and the samples were then washed in dH2O to remove
residual NaCl and centrifuged at 1500 x g for 10 minutes. Washing was repeated for a total of three
washes. The digested DAT was resuspended in 0.2 M acetic acid to achieve a stock suspension
concentration of 50 mg of DAT/mL and agitated overnight at 37 ⁰C. The DAT suspension was left to rest
for 24 h at 4 ⁰C, and then homogenized with a Fisher Scientific Power Gen 125 (Fischer Scientific,
Hampton, NH), and stored at 4 ⁰C until use.
To generate coatings, the DAT suspension was diluted to 25 mg/mL using 0.2 M acetic acid, and
carefully layered over TCP at 125 µL/cm2. DAT coatings were air dried for a minimum of 24 h. Coatings
were washed 3 times by adding, gently swirling, and discarding PBS to remove residual acetic acid.
Coatings were equilibrated overnight in Mesencult™ media + supplement (Stemcell Technologies,
Vancouver, BC, Canada) at 37 ⁰C prior to cell seeding.

2.1.3 DAT Microcarrier Fabrication

To prepare the microcarriers, the DAT suspension was diluted with acetic acid to achieve a working
concentration of 35 mg/mL, loaded in a 10 mL syringe, and attached to a 25G winged infusion set (BD
medical, Mississauga, ON, Canada) secured on a syringe pump (PHD 22/2000 infusion, Harvard
Apparatus, Holliston, MA) (Figure. 2.2). A Dewar flask containing liquid nitrogen was placed under the
needle and positioned 5 cm above the liquid nitrogen. A voltage of 16 kV was applied to the needle tip
and the DAT suspension was electrosprayed into liquid nitrogen at a rate of 30 mL/h. Microcarriers were
collected in 50 mL conical tubes and lyophilized for a minimum of 48 h. Microcarriers were resuspended
in 100% ethanol and stored at 4 ⁰C until use.
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A

B

Figure 2.2 Overview of electrosparying used to generate DAT microcarriers. (A) Experimental set-up
showing high voltage power supply, syringe pump, liquid nitrogen, infusion needle, DAT suspension, and
aluminum foil collector in a Dewar flask. (B) Schematic showing experimental set up of voltage range,
infusion rate, and distance between liquid nitrogen and needle tip. Figure obtained with permission
from191.
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2.2 BM-MSC Isolation and Seeding on DAT Scaffolds
2.2.1 BM-MSC Isolation and Expansion
Human bone marrow aspirates were obtained from healthy donors with informed consent from the
London Health Sciences Centre (University Hospital, London, Ontario). Hypaque-ficoll centrifugation
was used to isolate mononuclear cells (MNC) and seeded on tissue-cultured plastic (TCP) at 270,000
cells/cm2. Adherent colony forming unit-fibroblast (CFU-F) were established in Amniomax™ +
supplement (Life Technologies, Calrsbad, CA). At passage 2, BM-MSC were cryopreserved. All
experiments were performed using passage 4 cells when 80-85% confluency was reached in a T75 flask.

2.2.2 BM-MSC Seeding on DAT Coatings
The DAT suspension was coated on 6-well plates as previously described (2.1.2). Following 4 days
expansion, BM-MSC in a T75 were detached using 2 mL of Trypsin-LE express (Gibco, Invitrogen,
Carlsbad, CA) with 5 minutes incubation at 37 ⁰C. Enzymatic digestion was arrested using PBS + 5%
FBS, and the cells were collected in a 50 mL conical tube. The sample was centrifuged at 350 x g for 7
minutes, counted using a Countess II automated cell counter (Thermofischer Scientific, Waltham, MA)
and resuspended in 1 mL of supplemented Mesencult™ media. Next, 35,000 MSC were added per DAT
coated well in 1 mL of Mesencult™ media. BM-MSC were also cultured on TCP alongside DAT coated
wells as a control, and media was replaced every 3 days. MSC were cultured for a 1-week period to be
assessed for viability and cell surface marker expression. Media was changed every 3 days.

2.2.3 BM-MSC Seeding on DAT Microcarriers
Prior to cell seeding, microcarriers were weighed to have 5 g/flask and rehydrated over a period of 3 days
using an ethanol series diluted in PBS (100% - 0% in 5% increments). Microcarriers were equilibrated in
a CELLSPIN flask (INTEGRA Biosciences AG, Switzerland) in 25 mL of complete Mesencult™ media
overnight in a 37 ⁰C incubator. BM-MSC were trypsin-detached as previously described and 1.25 million
cells (250,000 cells/g of microcarriers) were resuspended in 25 mL of complete Mesencult™ media and
added to equilibrated microcarriers to achieve a total volume of 50 mL. A previously published 12 h
seeding regimen was utilized to facilitate BM-MSC attachment120. Briefly, microcarriers were
30

intermittently stirred for 2 minutes at 25 rpm every 30 min for 3 h, followed by 6 h of static rest , and then
another 3 h of intermittent stirring at 25 rpm. After seeding, the cells were cultured under continuous
dynamic conditions at 25 rpm for a period of 1 week, and media was replaced every 3 days.

2.3 BM-MSC Survival Pilot Study
2.3.1 Extraction from DAT Coatings for Viability and Cell Counting
To confirm that the DAT coatings had a bioactive effect on BM-MSC, a pilot study was performed to
evaluate their effects on cell viability and growth. At days 1, 3, and 7, media was collected, and wells
were washed with 1 mL of PBS, the wash also collected to collect detached non-viable cells. The cells
were trypsin-detached using 1 mL of TrypLE Express™/ well for 10 minutes at 37 ⁰C. Enzymatic activity
was blocked using 3 mL of PBS + 5% FBS, then the wells were rinsed with 6 mL of PBS + 5% FBS. The
mixture was then filtered using a 50 µm nylon mesh filter to remove large fragments of digested DAT.
The cells were then centrifuged at 350 x g for 7 minutes and resuspended in PBS + 5% FBS.

2.3.2 Cell Viability Counts
Following extraction, cells were resuspended in 100 µL of Annexin V binding buffer (BioLegend, San
Diego, CA) and counted using an automatic cell counter. Cells were then topped up to 300 µL of
Annexin-V binding buffer and each tube received 1 µL of 1 mg/mL Calcein-AM (diluted 1:1000 in
PBS+5% FBS) (Sigma Aldrich, St. Louis, MO), a marker for live cells, 4 µL of BV 421 Annexin-V 2.2
µg/mL (BioLegend, San Diego, CA), a marker for apoptotic cells, and 2 µL (diluted 1:10 in PBS) of
5mM DRAQ5 (Thermo Fisher, Waltham, MA), a marker for nucleated cells used to distinguish cellular
events from scaffold debris. Cells were stained at RT for 20 minutes, washed with 1 mL of Annexin V
binding buffer, and centrifuged at 350 x g for 7 minutes. Samples were resuspended in 300 µL of
Annexin V binding buffer and analyzed by flow cytometry. All reagents used are defined in Table 2.1.
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2.3.3 MSC Imaging on DAT substrates
BM-MSC were seeded as previously outlined on glass cover slips coated with DAT or uncoated as a
control. At day 7, cells were washed with PBS, and a staining cocktail was prepared by adding 2 µL
Calcein-AM and 4 µL DRAQ5 in 2 mL of PBS. Then 500 µL of cocktail was added to each well and
stained for 30 minutes in 37 ⁰C incubator, rinsed 2x with PBS, and imaged using multiphoton microscopy
(Nikon A1R MP+ Multiphoton Upright Scope). Imaging of BM-MSC on DAT microcarriers was
performed at day 3. Microcarriers were resuspended in 1 mL of staining cocktail, incubated for 30
minutes at 37 ⁰C, rinsed twice with PBS, mounted on a cover slip and imaged using confocal microscopy
(Olympus FluoView™ FV1000 confocal microscope).

2.4 BM-MSC Phenotypic Analyses
Following the pilot study, more advanced analyses involving dynamic culture were performed. To
determine whether the DAT substrates influenced BM-MSC phenotype, ALDH-activity and cell surface
marker expression was performed on BM-MSC at day 0 (prior to seeding) and at days 3 and 7. All
reagents used are described in Table 2.1. Analyses were performed using flow cytometry (BD™ LSR II
(BD Biosciences, San Jose, CA) at the London regional flow cytometry facility (LRFCF) and positive
gating was achieved using fluorescence minus-one (FMO). Data was analyzed using FlowJo software
(FlowJo LLC, Ashland, OR).

2.4.1 Extraction from DAT Coatings and Microcarriers for MSC Phenotype Analyses
ALDH-activity and cell surface marker analyses were performed on BM-MSC cultured on DAT
microcarriers, DAT coatings, or TCP. To achieve complete enzymatic digestion of the scaffolds, samples
of BM-MSC cultured on DAT coatings or TCP collected at days 1, 3 and 7 were digested using 1 mL of
Liberase TL (Sigma-Aldrich, St. Louis, MO). DAT microcarriers were collected in a 15 mL falcon tube
and resuspended in 1 mL of Liberase TL. The samples were digested for 1 h at 37 ⁰C and gently mixed
every 10 minutes to ensure scaffold digestion. Enzymatic activity was arrested using PBS + 5% FBS, and
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the samples were filtered using a 50 µm nylon mesh filter and centrifuged at 350 x g for 7 minutes and
resuspended in PBS + 5% FBS.

2.4.2 Stromal Cell Surface Marker Analyses
The effects of culturing on the DAT substrates on the expression of the stromal surface markers CD73,
CD90, and CD105 was assessed on samples that contained DRAQ5 to exclude scaffold debris from
analyses. Following cell extraction, each tube contained 300 µL of PBS + 5% FBS and sequentially
received 4 µL of the following antibodies: BV 421 100 µg/mL CD73 (BioLegend, San Diego, CA), FITC
200 µg/mL CD90 (BioLegend, San Diego, CA), and PE/Dazzle 100 µg/mL CD105 (BioLegend, San
Diego, CA), and 2 µL of DRAQ5. Samples were incubated at 4 ⁰C for 30 minutes, washed with 4 mL of
PBS + 5% FBS and centrifuged at 350 x g for 7 minutes. Samples were resuspended in 300 µL of PBS +
5 % FBS and analyzed by flow cytometry.

2.4.3 Cell Surface Marker Analyses
The effects of culture on DAT substrates CD146 and CD271 expression was assessed on samples that
were stained with DRAQ5 to eliminate scaffold debris and Calcein-AM to select for viable cells.
Following cell extraction, each tube contained 300 µL of PBS + 5% FBS and sequentially received 5 µL
of FITC 300 µg/mL CD271 (BioLegend, San Diego, CA) and PE 200 µg/mL CD146 (BD Biosciences,
San Jose, CA), 1 µL of Calcein-AM, and 2 µL of DRAQ5. Samples were incubated at RT for 30 minutes,
washed with 4 mL of PBS + 5% FBS and centrifuged at 350 x g for 7 minutes. Samples were resuspended
in 300 µL of PBS + 5 % FBS and analyzed by flow cytometry.

2.4.4 ALDH-activity analyses
Cells were resuspended in 300 µL of PBS + 5% FBS and sequentially stained with 1 µL of Calcein-AM
and 2 µL of DRAQ5 at RT for 20 minutes, washed with 4 mL of PBS + 5% FBS and centrifuged at 350 x
g for 7 minutes and resuspended in 300 µL of Aldefluor assay buffer (StemCell Technologies,
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Vancouver, BC, Canada). Next, 1 µL of Aldefluor was added to each sample and incubated at 37 ⁰C for
30 minutes. Samples were centrifuged at 350 x g for 7 minutes and resuspended in 300 µL of Aldfeluor
assay buffer. To establish positive ALDH gating, FMOs were generated using an ALDH-stained sample
that also received DEAB (N-diethylaminobenzaldehyde, inhibitor of ALDH) as per the manufacturer’s
protocol, and analyzed by flow cytometry.

TABLE 2.1 FLUORESCENT ANTIBODY/MOLECULE PRODUCT SPECIFICATION FOR FLOW CYTOMETRY
Antibody/Molecule

Fluorophore

Clone

Catalog #

Company

Phosphatidyl Serine
binding protein –
Annexin-V

BV421

N/A

640924

Biolegend, San
Diego, CA

Acetoxymethyl EsterCalcein-AM

Calcein-AM

N/A

17783

Sigma Aldrich, St.
Louise, MO

DNA Dye – DRAQ5

DRAQ5

N/A

62251

Thermo Fisher,
Waltham, MA

Monoclonal mouse antihuman CD73

BV421

AD2

344008

Biolegend, San
Diego, CA

Monoclonal mouse antihuman CD90

FITC

5E10

328108

Biolegend, San
Diego, CA

Monoclonal mouse antihuman CD105

PE/Dazzle

43A3

3233224

Biolegend, San
Diego, CA

Monoclonal mouse antihuman CD271

FITC

ME20.4

345104

Biolegend, San
Diego, CA

Monoclonal mouse antihuman CD146

PE

P1H12

550315

BD Biosciences, San
Jose, CA

Aldefluor

BODIPYaminoacetaldehyde
(BAAA)

N/A

01700

Stem Cell
Technologies,
Vancouver, BC

Dead cell dye – 7AAD

7AAD

N/A

420404

Biolegend, San
Diego, CA

Azide fluorophore

Pacific Blue

N/A

C10418

Thermofisher,
Waltham, CA
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2.5 In Vitro Pro-angiogenic Secretory Assessment
To assess whether culture on the DAT substrates modulated the pro-angiogenic paracrine effects of BMMSC, cells were cultured under the different conditions and conditioned media (CdM) was generated in
basal MesencultTM media (i.e. without the supplements). Collected CdM was concentrated via
centrifugation and supplemented onto human microvascular endothelial cells (HMVEC) cultured under
growth factor-free conditions. The ability of CdM to affect HMVEC proliferation, survival, and tubule
formation was assayed using the following protocols.

2.5.1 Generating Concentrated CdM
BM-MSC were seeded on DAT-coated or uncoated T25 flasks at 625,000 cells/flask with 4 mL of fully
supplemented Mesencult™ media and placed in a 37 ⁰C incubator overnight to allow for cell attachment.
A DAT-coated T25 flask not seeded with cells was included as a scaffold-only control. Similarly, 2.5 g of
DAT microcarriers were weighed, and seeded with 625,000 cells in a total of 30 mL of supplemented
Mesencult™ media. After equilibration, cells were washed 5 times with PBS, ensuring complete removal
of growth factors, and Mesencult™ Basal media (without supplement) was added to each sample, 4 mL in
each T25 and 30 mL in the CELLSPIN flask. Flasks were placed in the 37 ⁰C incubator and media was
conditioned for 48 h. Collected CdM was filtered through a 40 μm nylon mesh filter, loaded into
Amicon®Ultra-15 3 kDA centrifugal filters (Millipore Sigma, Burlington, MA), and centrifuged at 3220
x g at 4 ⁰C for 45 minutes for the 4 mL samples and 2 hours for the 30 mL DAT microcarrier samples, to
achieve a final volume of 400 μL of concentrated CdM per group, and stored in -80 ⁰C. Before use, CdM
samples were thawed at 4 ⁰C for 30 – 45 minutes.

2.5.2 HMVEC Culture with BM-MSC CdM
HMVEC were expanded in complete endothelial growth medium-2 media (EGM-2 = endothelial basal
media-2 + 5% FBS, IGF, bFGF, EGF, and VEGF, Lonza, Morrisville, NC) and passaged in T75s until
80-85% confluency was reached. All experiments were performed using HMVEC at passage 7. At
passage 6, HMVEC were detached with trypsin by adding 2 mL of TrypLE and incubating in 37 ⁰C for 5
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minutes and inactivated using PBS + 5% FBS. Cells were centrifuged at 240 x g for 5 minutes,
resuspended in 1 mL of EGM-2 media and counted. HMVEC were seeded at 60,000 cells per well in a
12-well plate containing 500 μL of EGM-2 media. The next day, EGM-2 media was removed, and wells
were washed with 500 μL of PBS 3x, to ensure the removal of residual growth factors. Next, 450 μL of
EBM-2 media was added to each well with 50 μL of CdM to achieve a 10% supplement. A no CdM
control was supplemented with 50 μL of unconditioned Mesencult™ Basal media. HMVEC were
harvested at days 1 and 3 for viability and proliferation assessment.

2.5.3 HMVEC Viability
At days 1 and 3, HMVEC were harvested and their viability was assessed. Wells were first rinsed with
500 μL of PBS, rinse was collected to obtain detached non-viable cells. Then 300 μL of TrypLE was
added to each well and incubated at 37 ⁰C for 7 minutes. Next, digestion was blocked and rinsed with 1
mL of PBS + 5% FBS. The samples were then centrifuged at 240 x g for 5 minutes and resuspended in
300 μL of Annexin V binding buffer. The samples sequentially received 4 μL of BV 421 Annexin V and
5 μL of 50 µg/mL 7-AAD (dead cell marker, Biolegend, San Diego, CA) and were incubated for 20
minutes at RT. Finally, the samples were washed with 1 mL of Annexin V binding buffer, centrifuged at
240 x g for 5 minutes, and resuspended in 300 μL of Annexin V binding buffer and analyzed by flow
cytometry.

2.5.4 HMVEC Proliferation
Proliferation was assessed using the EdU Assay (5-ethyl-2’-deoxyuridine). EdU is a thymidine analogue
incorporated into the DNA of cells during S-phase and can be detected via conjugation to an Azide
fluorophore. The Click-iT™ EdU Cell proliferation flow cytometry assay kit (Thermo Fisher, Waltham,
MA) was used for this assessment. At 24 h prior to cell collection, 1 μM of EdU was added to each well.
After 1 and 3 days of culture, cells were harvested as previously described, and resuspended in 500 μL of
10% buffered formalin fixation buffer for 5 minutes and blocked with 1 mL of PBS + 5% FBS. The
samples were centrifuged at 400 x g for 7 minutes and resuspended in 100 μL of 1x saponin
permeabilization buffer and incubated at RT for 15 minutes. The Click-it™ reaction utilizing copper (II)
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sulfate (CuSO4) was used to conjugate incorporated EdU to the Azide fluorophore Pacific Blue™ as per
manufacturer’s instructions. The frequency of EdU+ cells was analyzed by flow cytometry. EdU positive
cells were gated based on FMOs that did not receive CuSO4.

2.5.5 HMVEC Tubule Formation
Geltrex™ lactose dehydrogenase elevating virus (LDEV)-Free Reduced Growth Factor Basement
Membrane Matrix (Thermo Fisher, Waltham, MA) was thawed overnight on ice at 4 ⁰C. Pipette tips and a
24-well plate were pre-chilled at -20 ⁰C for 20 minutes to keep the surfaces cold. While working on an ice
block, 200 μL of Geltrex™ was added to each well, and the plate was gently swirled until an even layer
coated the well. The plate was then incubated at 37 ⁰C for 2 h to allow the Matrigel™ to solidify.
HMVEC obtained as previously described, were resuspended in EBM-2 Media, and each well of a 24well plate received 30,000 HMVEC in 360 μL of EBM-2 media (positive control received 30,000
HMVEC in 400 µL of EGM-2 media) with 40 μL of CdM to achieve a 10% supplement. The plates were
incubated at 37 ⁰C, and after 24 h, 5 photos were taken per well, and tubule formation was quantified by
blinded manual counting of tubule branch points using ImageJ software.

2.6 Directed In Vivo Angiogenesis Assay (DIVAATM)
A DIVAATM kit (R&D Systems, Minneapolis, MN) was used to assess endothelial cell (EC) recruitment
into DIVAA inserts supplemented with CdM generated by BM-MSC cultured on DAT substrates
compared to TCP. The DIVAATM protocol was performed as per the manufacturer’s instructions. Briefly,
DIVAATM inserts were loaded with 20 µL basement membrane extract supplemented at 10% with CdM.
Inserts containing VEGF/FGF served as a positive control. DIVAATM inserts were subcutaneously
implanted into the flanks of NOD/SCID mice. Studies were approved by the Human Studies Research
Ethics Board at Western University (see Appendix. 2). After 14 days, the mice were euthanized and EC
infiltration into the DIVAA™ inserts was quantified by FITC-lectin uptake as per the manufacturer’s
instructions using a SpectraMax plate reader (Molecular Devices, Sunnyvale, CA). Results shown in
Supplementary figure 1.
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2.7 CdM Proteomic Analyses
2.7.1 CdM Protein Extraction and Digestion
To prepare CdM for proteomic analysis, ~100 µL of CdM were lyophilized and reconstituted in 8 M urea,
50 mM ammonium bicarbonate (AMBIC), 10 mM dithiothreitol (DTT), and 2% sodium dodecyl sulfate
(SDS) lysis buffer. Proteins were sonicated with a probe sonicator (10 X 0.5 s pulses; Level 1) (Fisher
Scientific, Waltham, MA), and reduced in 10 mM DTT for 30 minutes at RT. Samples were then alkylated
in 100 mM iodoacetamide for 30 minutes at RT in the dark and precipitated in chloroform/methanol. Onpellet in-solution protein digestion was performed in 100 µL 50 mM AMBIC (pH 8) by adding
Trypsin/LysC (Promega, Madison, WI) in a 1:50 ratio to precipitated proteins. Proteins were incubated at
37 °C overnight (~20 h) in a ThermoMixer C (Eppendorf, Hamburg, Germany) at 900 rpm before acidifying
to pH 3 - 4 with 10% formic acid (FA). Salts and detergents were removed from peptide samples using C18
stagetips made in-house. Briefly, 10 layers were stacked into 200 µL pipette tips and rinsed with ice-cold
methanol. Stagetips were conditioned with Solution A (80/20/0.1% acetonitrile(ACN)/Water/Trifluoic acid
(TFA)), followed by Solution B (5/95/0.1% ACN/Water/TFA) prior to loading ~20 µg of peptides
resuspended in solution B. Duplicate washes were performed with solution B prior to elution of peptides
using solution C (80/20/0.1% ACN/Water/FA) and final elution using a 50/50 mixture of ACN/0.1%FA.
Peptides were centrifuged at 45 °C under vacuum and resuspended in 0.1% FA prior to quantification by
bicinchoninic acid assay (BCA).

2.7.2 Ultraperformance Liquid Chromatography (UPLC) Coupled to Tandem Mass Spectrometry
(LC-MS/MS)
Following protein quantification by BCA, samples were injected into LC-MS/MS to analyze proteomic
composition. Peptides were analyzed using a nanoAquity UHPLC M-class system (Waters, Wilfrod, MA)
connected to a Q Exactive mass spectrometer (Thermo Scientific, Waltham, MA) using a nonlinear
gradient. Buffer A consisted of water/0.1% FA and Buffer B consisted of ACN/0.1% FA. Peptides (~1 µg
estimated by BCA) were initially loaded onto an ACQUITY UPLC M-Class Symmetry C18 Trap Column
(Thermo Scientific, Waltham, MA), 5 µm, 180 µm x 20 mm and trapped for 5 minutes at a flow rate of 5
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µL/min at 99% A/1% B. Peptides were separated on an ACQUITY UPLC M-Class Peptide BEH C18
Column (130Å, 1.7µm, 75µm X 250mm) operating at a flow rate of 300 nL/min at 35 °C using a non-linear
gradient consisting of 1-10%B,10-20%B,20-30%B,30-40%B,40-50%B,60-70%B,80-90%B, for 10 minute
intervals before cyclic washing between 5-95%B. Settings for data acquisition on the Q Exactive Plus are
outlined in Table 2.2.

2.7.3 Proteomic Data Analysis
MS raw files were searched in MaxQuant (1.6.5.0) using the Human Uniprot database (reviewed only,
updated November 2020). Cleavage was set to semi-specific and I=L. Cysteine carbamidomethylation
was set as a fixed modification. Oxidation (M), N-terminal acetylation (protein), and deamidation (NQ)
were set as variable modifications (max. number of modifications per peptide = 5) and all other setting
were left as default. Precursor mass deviation was left at 20 ppm and 4.5 ppm for first and main search,
respectively. Fragment mass deviation was left at 20 ppm. Protein and peptide false discovery rate (FDR)
was set to 0.01 (1%) and the decoy database was set to revert. The match-between-runs feature was
utilized across all sample types to maximize proteome coverage and quantitation. Datasets were loaded
into Perseus (1.6.15) and proteins identified by site; reverse and potential contaminants were removed.
Protein identifications with quantitative values in >50% samples across groups (DAT coatings, TCP, or
DAT Microcarriers) were retained for downstream analysis unless specified elsewhere. Missing values
were imputed using a width of 0.3 and down shift of 1.8 to enable statistical comparisons. Gene-ontology
enrichment analyses were performed using open-source Metascape (Metascape.org).
TABLE 2.2 PARAMETERS FOR Q EXACTIVE PLUS DATA ACQUISITION.
Parameter
Orbitrap Resolution (MS1)
Mass Range
MS1 Injection Time
MS1 AGC Target
Lock Mass
MS2 Detection
MS2 Resolution
MS2 AGC Target
MS2 Injection Time
Loop Count
Isolation Width
Isolation Offset
MS2 Activation
Normalized Collision Energy
Dynamic Exclusion
Minimum AGC Target

Parameter Setting
70K
300-1500
250ms
3E+06
445.120025
FT
17,500
1e5
25ms
15
1.4 m/z
0.5 m/z
HCD
27
15
2.00E+03
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MS2 Intensity Threshold
Exclusion Duration
Charge Exclusion
Polarity

8.0E+04
20s
Unassigned,1,7,8
Positive

2.8 Statistical Analyses
Statistical analyses were performed using a two-way ANOVA, unless otherwise stated, followed by
Tukey’s post hoc multiple comparisons test. For tubule formation and DIVAATM experiments, a one-way
ANOVA was performed. All calculations were performed using GraphPad Prism 7 software.
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Chapter 3.0 Results
3.1 DAT Coatings Supported the Growth and Attachment of BM-MSC
Culture on tissue-culture plastic (TCP) does not provide complex extracellular matrix (ECM)-cell
interactions that are known to influence cell survival, growth, and differentiation49,189,192. Thus, in this
project, ECM-rich decellularized adipose tissue (DAT) scaffolds were used as an alternative culturing
platform. A pilot study was first performed in which bone marrow-mesenchymal stromal/stem cells (BMMSC) were cultured on DAT coatings under static conditions before advancing to more in depth studies
involving dynamic culture. While DAT constructs have previously been shown to support the growth of
adipose-derived stromal/stem cells (ASC)120,138,175,193, this was the first time BM-MSC were investigated
on the DAT platform. Thus, the purpose of this study was to determine if there were beneficial effects on
BM-MSC following culture on DAT coatings.
BM-MSC were expanded on TCP and then seeded onto DAT coatings or TCP controls and cultured over
1-week in vitro. To label live versus apoptotic/dead cells, Calcein-AM and Annexin-V were used
respectively, and flow cytometry was performed to quantify the frequency of viable (Calcein+/Annexin-)
and non-viable cells (Calcein-/Annexin+) (Figure 3.1A,B). The mean frequency of non-viable BM-MSC
was significantly decreased at day 7 when cultured on DAT coatings compared to TCP (19.2 ± 6.6 % vs
33.5 ± 9.9%, *p<0.05, Figure 3.1C). Applying cluster gating, the mean frequency of viable BM-MSC
(Calcein+/Annexin-) was 73.4 ± 10.4% when cultured on DAT coatings, which was not significantly
different compared to TCP at 62.0 ± 11.7% (p=0.076, Figure 3.1D).
Hemocytometer cell counting was combined with the viable cell frequency to obtain total live cell
numbers. Total viable BM-MSC counts were significantly increased at day 7 when cultured on DAT
coatings compared to TCP (396,445 ± 99,075 live cells vs 221,475 ± 42,586 live cells, ***p<0.001,
Figure 3.1E). Thus, growth of BM-MSC on DAT coatings resulted in a reduced frequency of dead BMMSC and increased the total yield of viable BM-MSC after 7 days of static culture.
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3 3.2 Visualization of BM-MSC Attachment on TCP and DAT Bioscaffolds
Following the demonstration of increased BM-MSC expansion on DAT coatings, cells were seeded on
TCP or DAT coatings under static culture, and on DAT microcarriers under dynamic culture conditions
and cell attachment was visualized for all conditions. Representative multiphoton confocal images
showed robust BM-MSC attachment across all conditions (Figure 3.2). Qualitative analyses compared at
day 7 using multiphoton microscopy staining for DRAQ5 (cell nuclei) and Calcein-AM (live cells)
showed an elongated and spindled-shaped appearance of BM-MSC on glass coverslips (Figure 3.2B). In
contrast, a qualitatively less elongated appearance was observed on 3D DAT coatings (Figure 3.2A).
Notably, DAT coatings demonstrated three-dimensional growth, and the coatings provided greater
volume for the cells to occupy. Representative analysis at day 3 using confocal microscopy of BM-MSC
on DAT microcarriers (Figure 3.2C), showed extensive cell attachment on the spherical microcarriers
following dynamic culture conditions in a spinner flask.
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Figure 3.1 The yield of viable BM-MSC was increased after culture on DAT coatings compared to
TCP. Representative flow cytometry plots of Calcein-AM+ (live cells) and Annexin-V+ (dead or apoptotic
cells) at day 7 comparing BM-MSC cultured on (A) DAT coatings or (B) TCP. (C) The frequency of dead
BM-MSC was significantly decreased after 7 days of culture on DAT coatings compared to TCP. (D)
Frequency of live BM-MSC cultured on DAT coatings compared to TCP. (E) BM-MSC viable cell count
was increased at day 7 when cultured on DAT coatings compared to TCP. Data represent Mean ± SD using
BM-MSC purified from 6 different (N=6) human BM samples (*p<0.05, ***p<0.001). Analysis for
statistical significance was performed using a two-way ANOVA followed by Tukey’s post hoc multiple
comparisons test.
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Figure 3.2 Representative photomicrographs showing BM-MSC grown on DAT coatings or uncoated
glass coverslips under static conditions, and on DAT microcarriers under dynamic conditions.
Multiphoton microscopy comparing live BM-MSC (Calcein-AM green) with cell nuclei labelled by DRAQ5
(blue) grown on (A) DAT coatings or (B) glass coverslip imaged at day 7 at 25x magnification. BM-MSC
had a less spindle-shaped morphology when cultured on DAT compared to glass coverslip. (C) Confocal
microscopy visualizing live BM-MSC (Calcein-AM green) on DAT microcarriers at day 3 imaged at 10x
magnification. All scale bars = 100 µm.
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3.3 The Fraction of BM-MSC Expressing Pericyte and Stromal Markers was not
Significantly Altered when Cultured on DAT Constructs
The International Society of Cell Therapy (ISCT) specifies that one of the minimal criteria defining MSC
is >95% cell surface expression of the stromal markers CD73 (ecto-5’-nucleotidase) , CD90 (Thy-1), and
CD105 (Endoglin)79,87. Additionally, CD146 (MCAM) is associated with MSC vascular smooth muscle or
pericyte commitment and ability to differentiate into supportive pericytes that wrap around and stabilize
blood vessels80,194. BM-MSC seeded on DAT coatings, TCP, or DAT microcarriers were therefore
assessed for the expression of these stromal markers (CD73, CD90, and CD105), as well as the pericyte
marker (CD146), at the time of seeding (day 0 expression) and after 3 and 7 days of culture. Stromal
marker expression was similar on BM-MSC cultured on the DAT substrates or TCP over a 1-week
culturing period (>95%) and not significantly different compared to expression at day 0 just prior to
seeding (Figure 3.3A-C). CD146 expression was not significantly different between groups and not
significantly different compared to expression at day 0. At day 7, the mean frequency of CD146+ BMMSC were 77.7 ± 4.8%, 87.6 ± 3.6%, and 69.6 ± 14.9% when cultured on DAT coatings, TCP, and DAT
microcarriers respectively (Figure 3.3D). Therefore, culturing on the DAT under either static or dynamic
conditions did not alter the expression of the expected stromal or pericyte markers compared to traditional
static culture on TCP.
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Figure 3.3 BM-MSC expression of stromal and pericyte markers was maintained throughout culture
on DAT substrates. Analysis of cell surface markers showing BM-MSC expression of (A) CD73, (B)
CD105, and (C) CD90 was not significantly altered by culture on DAT coatings or DAT microcarriers.
(D) The pericyte marker CD146 was not significantly changed on BM-MSC when cultured on DAT
coatings or DAT microcarriers. Data represent Mean ± SD using BM-MSC purified from 3-4 human BM
samples. Analysis for statistical significance was performed using a two-way ANOVA followed by
Tukey’s post hoc multiple comparisons test.
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3.4 The Frequency of BM-MSC with High Aldehyde Dehydrogenase Activity was
better Maintained on DAT Coatings under Static Conditions
ALDH is an intracellular enzyme involved in the detoxification of reactive aldehydes into less reactive
acetates and has been previously shown to be a conserved functional marker of primitive mesodermal
progenitor cells of multiple lineages72,195,196. Thus, the purpose of these experiments was to assess the
ability of DAT constructs to maintain ALDH-activity during culture, as a conserved functional progenitor
cell characteristic. Representative flow cytometry plots for cytosolic ALDH-activity within BM-MSC
cultured on DAT coatings, TCP or on DAT microcarriers after 7 days culture are shown in Figure 3.4AC. At day 0 prior to seeding (Figure 3.4D), the frequency of ALDHhi BM-MSC was 23.7 ± 2.2 %, and
similar to previous studies from our lab195. After 3 days of culture, the frequency of ALDHhi BM-MSC
was not significantly different when cultured on DAT coatings (16.9 ± 7.5%) or DAT microcarriers (14.6
± 1.9%) compared to TCP (16.2 ± 7.1%) (Figure 3.4E) compared to day 0. Further, no significant
differences were observed between timepoints within groups. At day 7, the frequency of ALDHhi BMMSC when cultured on DAT coatings (16.4 ± 6.4%) was not significantly different compared to day 0
levels, while culture on TCP (8.6 ± 3.9%, ***p<0.001) and DAT microcarriers (12.4 ± 3.3%, *p<0.01)
resulted in significantly decreased frequencies of ALDHhi BM-MSC compared to day 0 levels (23.7 ± 2.2
%, Figure 3.4E). Therefore, culture of BM-MSC on DAT coatings under static conditions for 7 days best
maintained the frequency of ALDHhi BM-MSC compared to day 0 levels prior to seeding on the various
substrates.
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Figure 3.4 BM-MSC cultured on DAT coatings preserved BM-MSC with high ALDH-activity for
7 days. Representative flow cytometry plots showing ALDH-activity in BM-MSC after 7 days of culture
on (A) DAT coatings, (B) TCP, (C) DAT microcarriers, or at (D) day 0 prior to seeding. (E) Frequency
of ALDH-high BM-MSC when cultured on various substrates at day 3 was not significantly different
compared to Day 0. The frequency of BM-MSC that retained high ALDH-activity (a conserved progenitor
cell function) was not significantly changed on DAT coatings after 7 days of culture, while a decline was
observed TCP and DAT microcarriers compared to Day 0. Data represent Mean ± SD using BM-MSC
purified from 4 – 5 human BM samples (**p<0.01, ***p<0.001). Analysis for statistical significance was
performed using a two-way ANOVA followed by Tukey’s post hoc multiple comparisons test.
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3.5 BM-MSC Cultured on DAT Microcarriers Showed an Increased Fraction of
Cells Expressing the Cell Surface Marker CD271
CD271/LNGFR (low-affinity nerve growth factor receptor) has been postulated as a primitive cell surface
marker expressed on MSC early after isolation and is associated with increased clonogenic and
immunogenic MSC functions197,198. Although the association of CD271 as a primitive marker remains
controversial, analysis of CD271 expression was assessed on BM-MSC when cultured on DAT substrates
or TCP. After 3 days of culture on DAT microcarriers under dynamic conditions, the frequency of
CD271+ BM-MSC was significantly increased from 6.5 ± 4.4% at day 0 to 27 ± 11.5% at day 3
(****p<0.001, Figure 3.5E). Interestingly, culture of BM-MSC under static conditions for 3 days on DAT
coatings (5.4 ± 2.2%) or on TCP (0.77 ± 0.49%) showed that a significantly lower fraction of cells
expressed CD271 expression compared to culture on the microcarriers (****p<0.001, Figure 3.5E). After
7 days of culture, the frequency of CD271+ BM-MSC on DAT microcarriers was 11.6 ± 3.8% and was
not significantly different from day 0 levels, but remained significantly increased compared to static
culture on DAT coatings (2.5 ± 1.5% , *p<0.05) and TCP (0.44 ± 0.34%, **p<0.01). No significant
differences were observed between timepoints within groups. Collectively, these data suggested that
culture of BM-MSC on DAT microcarriers under dynamic conditions increased the fraction of cells that
expressed CD271.
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Figure 3.5 The fraction of BM-MSC that expressed CD271 was increased when the cells were
cultured on DAT microcarriers under dynamic conditions. Representative flow cytometry plots
showing CD271 expression (undifferentiated MSC marker) on BM-MSC at day 7 when cultured on (A)
DAT coatings, (B) TCP, (C) DAT microcarriers, or at (D) day 0 prior to seeding. The frequency of
CD271+ BM-MSC was significantly increased on DAT microcarriers compared to DAT coatings and TCP
across different time points (E). Data represent Mean ± SD using BM-MSC purified from 3 – 5 human
BM samples (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001). Analysis for statistical significance was
performed using a two-way ANOVA followed by Tukey’s post hoc multiple comparisons test.
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3.6 Conditioned Media Generated by BM-MSC on DAT Coatings Increased
Endothelial Cell Survival
MSC are known to secrete a variety of growth factors in vitro that support endothelial cell homeostasis96.
As such, the ability of the DAT to influence BM-MSC pro-angiogenic secretory potential in vitro was
assessed. Conditioned media (CdM) was generated from BM-MSC cultured on the different substrates
under serum-free conditions. Concentrated (10-fold) CdM was supplemented into human microvascular
endothelial cell (HMVEC) cultures in endothelial basal media-2 (EBM-2) with no growth factors or
serum, and the ability of CdM to influence HMVEC survival was determined by staining with 7-AAD
(dead cell marker) and Annexin-V (apoptotic cell marker) after 1 and 3 days of culture. After 1 day of
culture, the frequency of live HMVEC (Annexin-/7AAD-) was not changed between groups (Figure 3.6E).
At day 3, the frequency of live HMVEC was significantly decreased as compared to day 1 for all groups.
Additionally, at day 3, the frequency of HMVEC survival was significantly increased when HMVEC
were supplemented with CdM from cells cultured on DAT coatings (47.6 ± 7.9%) compared to
unconditioned EBM-2 (29.5 ± 10.1%, *p<0.05, Figure 3.6E). Interestingly, the frequency of HMVEC
survival was also significantly increased when supplemented with DAT coating CdM compared to TCP
CdM (31.4 ± 10.6%, *p<0.05) or unseeded DAT coating controls (28.1 ± 8.3%, **p<0.01, Figure 3.6E).
Lastly, no significant differences were seen in HMVEC survival when supplemented with DAT
microcarriers CdM (33.6 ± 19.8%, Figure 3.6E) compared to other groups.
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Figure 3.6 HMVEC survival was increased under serum-free conditions when cultures were
supplemented with BM-MSC CdM. Representative flow cytometry plots showing 7AAD (dead) and
Annexin-V (apoptotic) HMVEC after 3 days culture in EBM-2 media supplemented with CdM generated
by BM MSC on (A) DAT coatings, (B) TCP, (C) DAT microcarriers, or (D) unconditioned EBM-2
media. (E) At Day 3, HMVEC survival was significantly increased when supplemented with CdM
generated by BM-MSC on DAT coatings compared to CdM generated on TCP, DAT only, and
unconditioned EBM-2. Data represent Mean ± SD using BM-MSC purified from 6 – 8 human BM
samples. Abbreviations, CdM; conditioned media, EBM-2; endothelial basal media. Analysis for
statistical significance was performed using a two-way ANOVA followed by Tukey’s post hoc multiple
comparisons test.
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3.7 Conditioned Media Generated by BM-MSC Cultured on all Substrates had no
Effect on Endothelial Cell Proliferation
Next, the ability of BM-MSC CdM to stimulate endothelial cell proliferation in vitro was assessed via the
EdU uptake assay. HMVEC cultured under serum-free culture were supplemented with BM-MSC CdM
generated on the various substrates. At 24 hours prior to HMVEC harvest at days 1 and 3, cultures were
pulsed with EdU, and EdU uptake into proliferating HMVEC was quantified by EdU conjugation to the
Azide fluorophore Pacific Blue™ to quantify the fraction of proliferating cells by flow cytometry.
Representative flow cytometry detection of EdU+ cells that underwent DNA-replication since the pulse
period in HMVEC cultures supplemented with DAT coating CdM, TCP CdM, DAT microcarrier CdM, or
unconditioned EBM-2 media are shown in Figure 3.7A-D. Within groups the frequency of EdU+ HMVEC
were significantly decreased across time points. However, no significant changes in HMVEC EdU uptake
were observed between groups when supplemented with CdM generated by BM-MSC cultured under any
of the conditions studied (Figure 3.7E). Thus, HMVEC proliferation under serum-free conditions in vitro
was not augmented by supplementation with BM-MSC CdM generated under the various culture
conditions tested.
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Figure 3.7 HMVEC proliferation under serum-free conditions was not changed when supplemented
with BM-MSC CdM. Representative flow cytometry plots showing EdU uptake by HMVEC following a
24 hour EdU pulse when cultured in EBM-2 media supplemented with (A) DAT coatings CdM, (B) TCP
CdM, (C) DAT Microcarriers CdM, or (D) Unconditioned EBM-2 media. (E) Frequency of EdU+ HMVEC
supplemented with CdM generated by BM-MSC on various substrates showed no significant differences
between groups. Data represent Mean ± SD using BM-MSC purified from 6 – 8 human BM samples
Analysis for statistical significance was performed using a two-way ANOVA followed by Tukey’s post
hoc multiple comparisons test.
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3.8 Conditioned Media Generated by BM-MSC did not Influence Endothelial Cell
Tubule Formation under all Culture Conditions Studied
To assay for the ability of collected CdM to induce tubule formation, HMVEC were cultured on growth
factor reduced Geltrex™ and supplemented with CdM generated by BM-MSC under the conditions
previously described. After 24 hours, HMVEC tubule formation was imaged (Figure 3.8A-D), and blinded
counting of complete tubule branch points was performed. No significant differences in HMVEC tubule
branch points/cm2 were observed when supplemented with CdM generated by BM-MSC under any of the
conditions (Figure 3.8E).
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Figure 3.8 HMVEC tubule formation under serum-free conditions was not changed by supplementation with
BM-MSC CdM. Representative images of HMVEC tubule formation after 24 hours culture in growth factor reduced
Geltrex matrix supplemented with CdM generated by BM-MSC on (A) DAT coatings, (B) TCP, (C) DAT
Microcarriers, or (D) Unconditioned EBM media. (E) CdM derived from BM-MSC did not change HMVEC tubule
formation between groups. Data represent Mean ± SD using BM-MSC purified from 4 – 5 human BM samples.
Analysis for statistical significance was performed using a one-way ANOVA followed by Tukey’s post hoc multiple
comparisons test.
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3.9 BM-MSC Cultured on Various Substrates Secreted Unique Proteins
Following in vitro characterization of pro-angiogenic functions, CdM samples (N=3 / culture treatment)
underwent global secretome analyses using label-free, quantitative mass spectrometry (Figure 3.9A).
Total unique peptide and protein detection was statistically equivalent in CdM from DAT coatings (7449,
442) and TCP (8143, 585) showing excellent coverage, whereas a lower number of unique peptides and
proteins were detected in CdM from the DAT microcarriers (3260, 139) (Figure 3.9B, C). A total of 834
unique proteins were identified, with 53 proteins unique to DAT coatings CdM, 279 proteins unique to
TCP CdM, and 26 proteins unique to DAT microcarriers CdM (Figure 3.9D). Distinct secretory
signatures were substrate and culture condition dependent, as revealed by principal component analysis
(Figure 3.9E). BM-MSC cultured on DAT coatings or microcarriers showed unique secretory profiles that
were very consistent between different donors. In contrast, greater variability was observed with one
donor in the secretome of BM-MSC cultured on TCP. The PCA analysis showed a large difference in
component 1 (69.8%), which separated the DAT microcarriers CdM from the other two groups. In
contrast, the lower magnitude of component 2 (9.2%), which segregated the DAT coatings CdM from the
TCP CdM, suggests that the secretome in these two groups was more similar.
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Figure 3.9 Global secretome of BM-MSC was distinct when cultured on DAT coatings, TCP, or
DAT microcarriers. (A) Overview of experimental methodology showing collection, concentration,
lyophilization, proteolysis, and subsequent label-free MS quantification of CdM. Number of peptides (B)
and (C) proteins identified in CdM collected from BM-MSC cultured on different conditions. (D) A total
of 834 unique proteins were identified, of which 53, 279, and 26 were unique to DAT coatings, TCP, and
DAT microcarriers CdM respectively. (E) Principle component analysis revealed divergent proteomic
signatures of BM-MSC cultured on DAT coatings, TCP, or DAT microcarriers. Data represent Mean ±
SD using BM-MSC purified from 3 human BM samples.
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3.10 BM-MSC Cultured on DAT Coatings Secreted Factors Associated with
Wound Healing and ECM Remodelling Compared to BM-MSC Cultured on TCP.

Within the proteins that were co-expressed under all 3 conditions, volcano plots comparing DAT coatings
CdM to TCP CdM further revealed 79 proteins were increased in TCP CdM, whereas only 18 proteins
were increased in DAT coatings CdM and only 9 proteins were increased in DAT microcarriers CdM
compared to TCP CdM (>2-fold, p<0.05, Figure 3.10A,B). Upregulated proteins in TCP CdM and DAT
coatings CdM were also cross-referenced to Gene-ontology (GO) Biological Processes annotations199. In
the DAT coatings CdM eight factors were associated with regulation of wound healing or ECM
remodelling (Table 3.1). The other unique proteins included 4 ECM components (chondroadherin,
tenascin, proteoglycan, epoxide hydrolase), 2 immunomodulatory factors (mast cell carboxypeptidase and
neutrophil defensin), 2 enzymes (peptidyl isomerase and citrate synthase), and 2 proteins of unknown
function (c-type mannose receptor and plexin-domain containing protein). Enrichment association of GO
Biological Processes revealed upregulation of factors by BM-MSC on DAT coatings associated with
wound healing, ECM organization, epithelial cell proliferation, and gland development (Figure 3.10C).
Upregulated proteins in TCP CdM compared to DAT coatings CdM were associated with supramolecular
fibre organization, ECM organization, blood vessel morphogenesis, and negative regulation of cell
migration (Figure 3.10D). Upregulated peptides in TCP included D-dopachrome decarboxylase,
SERPINF1, Dickopff-related protein-1, MMP2, follistatin-related protein, and myeloid derived growth
factor. Analysis of peptides secreted by BM-MSC cultured on DAT coatings and DAT microcarriers
revealed that out of the 9 unique proteins in DAT microcarrier CdM, 5 were also upregulated on DAT
coatings CdM including, fibroblast activation protein (FAP), thrombospondin 4 (THBS4), fibromodulin
(FMOD), antithrombin-III (SERPINC1), and contactin-1 (CNTN1) (Figure 3.10E).
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TABLE 3.1 SELECT UPREGULATED PROTEINS SECRETED BY BM-MSC WHEN CULTURED ON DAT
COATINGS COMPARED TO TCP.
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Figure 3.10 BM-MSC secreted factors associated with wound healing and ECM remodelling when
cultured on DAT coatings compared to TCP. (A) Volcano plot comparing DAT coatings CdM to TCP
CdM showing 18 and 79 unique proteins respectively that were significantly increased >2.0-fold. (B)
Further comparison between DAT microcarriers CdM and TCP showing 9 and 350 unique proteins
respectively, that were significantly increased >2.0-fold. (C) Enrichment association revealed that BMMSC on DAT coatings secreted factors that were associated with wound healing, ECM organization,
epithelial cell proliferation, and gland development. (D) Upregulated proteins in TCP CdM were
associated with supramolecular fibre organization, ECM organization, blood vessel morphogenesis, and
negative regulation of cell migration. (E) Similar hits were identified in DAT coatings and DAT
microcarrier CdM compared to TCP, which included FAP, THBS4, FMOD, SERPINC1, and CNTN1.
GO enrichment analyses were performed using open-source Metascape (Metascape.org)199. Data
represent Mean ± SD using BM-MSC purified from 3 human BM samples (p<0.05).
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Chapter 4.0 Discussion
4.1 Summary of Observations
The following novel observations were uncovered during the course of my thesis experiments:
1) DAT coatings supported the attachment and growth of BM-MSC.

2) The fraction of cells expressing the defining BM-MSC stromal markers CD73, CD90, and
CD105, and the pericyte marker CD146, was not altered by culture on DAT substrates under
static or dynamic conditions.
3) The frequency of BM-MSC with high ALDH-activity was reduced relative to baseline levels at
the time of seeding with culture on TCP and better preserved with culture on DAT coatings.

4) The fraction of cells expressing low affinity nerve growth factor receptor (LNGFR or CD271)
was increased relative to baseline levels at the time of seeding by culture on DAT microcarriers
under dynamic culture conditions, but not by culture on DAT coatings under static conditions.

5) BM-MSC conditioned media (CdM) generated on DAT coatings under static conditions increased
HMVEC survival under serum-free conditions but did not alter HMVEC proliferation or tubule
formation in vitro.
6) BM-MSC cultured on DAT coatings had a secretome associated with enhanced wound healing,
ECM remodelling, epithelial cell proliferation, and gland development.
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4.2 Discussion of Observations
4.2.1 DAT Coatings Supported the Attachment and Growth of BM-MSC

While DAT constructs have previously been shown to support the growth of adipose-derived
stromal/stem cells (ASC)120,175,177,191, this was the first time that bone marrow-derived mesenchymal
stromal/stem cells (BM-MSC) were investigated on DAT platforms. Thus, a pilot study was performed to
confirm that the DAT coatings supported the attachment and growth of human BM-MSC under static
conditions before advancing to more in-depth studies involving dynamic culture. Culture on DAT
coatings reduced the frequency of non-viable BM-MSC and increased viable BM-MSC counts after a 7day period compared to culture on tissue culture polystyrene (TCP). The enhanced yield may be attributed
in part to favorable cell-ECM interactions associated with culturing on the DAT.
MSC possess a variety of cell surface receptors including integrins, which are critical in facilitating cellECM interactions150. Broadly, integrins are heterodimeric proteins consisting of α and β subunits, the
latter are involved in various cell-ECM interactions. These heterodimers can bind laminins, fibronectins,
GAG, and collagens200, which are ECM components that have been identified in DAT163,176,201. Binding
of integrins to ECM components has been shown to regulate survival, apoptosis, proliferation, and
migration in various cell types including MSC127,200. It was observed that the frequency of non-viable
BM-MSC was decreased and viable cell count was increased when cultured on DAT coatings compared
to TCP which maybe due to cell-ECM interactions. However future studies should further explore
whether culturing on the DAT coatings stimulated proliferation, prevented cell death, or resulted in both.
In addition to providing supportive biochemical cues, DAT coatings may have provided a greater surface
area for BM-MSC growth as compared to TCP, with a 3-D topography evident by multiphoton
microscopy. Cells cultured on TCP reached confluency by day 7, while it appeared that there was more
available volume for BM-MSC proliferation on the DAT, which likely contributed to the higher viable
BM-MSC yield. Multiphoton imaging also showed a qualitatively less elongated cell morphology in the
BM-MSC cultured on the DAT coatings as compared to TCP, where a more elongated-spindle shape was
observed. These differences may be attributed to differences in the cell densities due to greater surface
area, which can affect cell morphology202..
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4.2.2 Expression of BM-MSC Stromal Markers (CD73, CD90, and CD105) and the Pericyte
Marker (CD146) was not Altered by Culture on DAT Substrates under Static or Dynamic
Conditions.

The expression of defining MSC stromal markers, CD73, CD90, and CD105, was not altered by culturing
the BM-MSC on DAT substrates under static or dynamic conditions, indicating that prolonged culture on
DAT did not influence native MSC. Similarly, previous work in the Flynn lab observed no significant
differences in CD73, CD90, and CD105 expression on ASC following a 3-week expansion on DAT
microcarriers120. In addition, the pericyte marker CD146, found on MSC with vascular smooth muscle
commitment194 was not changed following culture on DAT constructs. Due to the ability of ECM to
support MSC primitive and non-differentiated phenotypes, it was hypothesized that prolonged culture on
TCP would result in decreased CD146 expression while a maintenance would be observed on DAT,
however this was not observed in these findings.

4.2.3 The Frequency of BM-MSC with High ALDH-activity was Reduced with Culture on TCP
and Preserved with Culture on DAT Coatings.

In addition to cell surface marker analyses, the effects of culturing on the DAT substrates on the function
of the self-protective enzyme aldehyde dehydrogenase (ALDH) was assessed. ALDH includes a large
family of enzymes which detoxify cellular aldehydes. The isoforms ALDH1A1 and ALDH1A3 are of
specific importance in MSC, as they regulate the production of retinoic acid (RA)203. RA induces
transcription of a variety of genes involved in cell differentiation, and hence regulating RA production is
crucial in maintaining progenitor cell fate204. As primitive progenitor cells differentiate, ALDH-activity is
gradually reduced, and as such ALDH has been used as a conserved progenitor cell functional marker to
select for cells with enhanced regenerative properties72. The Hess lab has previously shown that human
umbilical cord blood-derived ALDHhi cells restored limb perfusion in a femoral artery ligation (FAL)induced unilateral hindlimb ischemia model adapted to immunodeficient NOD/SCID mice72,196. Further,
MSC purified using high ALDH-activity mediated enhanced cell recruitment into implanted DIVAATM
inserts compared to ALDHlo MSC195. Thus, analysis of ALDH-activity in BM-MSC cultured on DAT was
performed.
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BM-MSC cultured on DAT coatings retained the frequency of cells with high ALDH-activity, as a
significant decrease from day 0 levels was observed after 7 days of culture on TCP. In contrast, the
frequency of ALDHhi BM-MSC was not significantly changed from day 0 levels after 7 days of culture on
DAT coatings. As previously described, MSC-based therapies face challenges during expansion, as cells
lose regenerative secretory capacity during the extensive proliferation required for translation to clinical
applications in humans49,205. This study suggests that DAT coatings may be a superior platform to expand
BM-MSC while retaining the regenerative marker ALDH.
Consistent with these findings, recent work in our lab showed an increase in frequency of ALDHhi cells
when human hematopoietic progenitor cells were cultured on DAT foams, which was associated with
differentiation towards the monocyte/macrophage lineage178. Additionally, Begum et al. previously
reported an increase in ALDHhi pancreatic ductal cells when cultured on type I collagen compared to TCP
due to enhanced α2β1 integrin signalling – a central integrin in the modulation of MSC fate206,207.
However, it is difficult to pinpoint exact components of DAT that maintain high ALDH-activity in BMMSC. Most likely, a complex interplay between various ECM components and MSC integrin interactions
are involved. Interestingly, culture on DAT microcarriers under dynamic conditions did not elicit a
similar response, as a decline in the frequency of ALDHhi BM-MSC was observed from day 0 expression
similar to TCP. This may be attributed to the impact of dynamic culture and additional exposure to shear
stress forces rather than the DAT substrate itself, as high ALDH-activity was preserved in BM-MSC
cultured on DAT coatings under static culture conditions. This may indicate that shear stress forces were
not optimized for the maintenance of high ALDH-activity in BM-MSC, and the effects of different
stirring rates on ALDH-activity should be investigated in future experiments.

4.2.4 The Fraction of BM-MSC Expressing LNGFR (CD271) was Increased by Culture on DAT
Microcarriers under Dynamic Culture Conditions, but not Through Culture on DAT Coatings
under Static Conditions

The fraction of cells expressing CD271, also known as low-affinity nerve growth factor receptor
(LNGFR), was assessed on the BM-MSC under the various culture conditions studied. CD271 has been
purported as a primitive MSC marker to enrich for undifferentiated cells that retain high proliferative
capacity from bone marrow sources197. Although, it should be noted that the association of CD271
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expression and primitive MSC function has yet to be proven. However, it has been shown that CD271
identifies a subset of MSC with enhanced immunomodulatory potential198. Smith et al. observed that ASC
selected for CD271 expression showed enhanced pro-angiogenic gene expression, while demonstrating
lower inflammatory gene expression than CD271- ASC208. In our analyses, a higher percentage of BMMSC expressed CD271 when cultured on DAT microcarriers compared to day 0. The frequency of BMMSC expressing this marker was also increased compared to DAT coatings and TCP throughout the 7day culture period. The significant change seen following culture on the DAT microcarriers is likely
attributed to dynamic culturing parameters, since an increase in CD271 expression from day 0 was not
observed when BM-MSC were cultured on DAT coatings under static conditions. It is possible that
increased shear stress from the spinner flask platform may increase CD271 expression on BM-MSC
through putative mechano-transduction signalling. A synergistic effect between DAT-integrin signalling
and MSC and shear forces may also account for these differences seen.
Additionally, CD271 is also a receptor for a variety of neutrotrophins including brain-derived
neutrotrophin factor (BDNF), neutrotrophin 3 (N3), neutrotrophin 4 (N4), and nerve growth factor
(NGF)209. Neutrotrophins are reported to play a major role in regulating survival, development, and
function of neurons and many other cell types through receptor tyrosine kinase (RTK) signalling210.
Criger et al., showed that subpopulations of MSC secrete BDNF and NGF, which promoted neuronal
survival and function in vitro211. Later Milczarek et al. found that CD271+ MSC express BDNF, NGF,
and a variety of other neutrotrophins212. We hypothesize that secreted neutrotrophins may be acting on the
MSC through an autocrine fashion. In this project, it was observed that the frequency of BM-MSC
expressing CD271 increased when cultured on DAT microcarriers, which may permit increased autocrine
signalling through CD271-mediated RTK signals that influence cell behaviour213. The importance of
CD271+ MSC in neuro-regeneration has been highlighted in clinical studies that showed intrathecal (IT)
and intravenous (IV) transplantation of autologous CD271+ MSC improved neural, cognitive, and motor
symptoms in epileptic patients212 and restored sensation and movement in a patient with spinal cord
injury214. Collectively, the findings in this thesis with CD271 expression warrant further investigation for
the use of DAT culturing platforms to generate BM-MSC for neuro-regeneration applications.
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4.2.5 BM-MSC CdM Generated on DAT Coatings Increased HMVEC Survival under Serumfree Conditions but did not Alter HMVEC Proliferation or Tubule Formation In Vitro

MSC are well recognized to secrete factors that promote angiogenesis in vivo and in vitro94. In this
project, the pro-angiogenic secretory functions of BM-MSC following culture on DAT constructs were
assessed in vitro. Conditioned media (CdM) was collected from the BM-MSC cultured statically on the
DAT coatings or TCP, or dynamically on the DAT microcarriers, under serum-free conditions. The
effects of supplementation with this CdM on the survival, proliferation, and tubule formation of human
microvascular endothelial cell (HMVEC) cultured under growth factor and serum-reduced conditions
were explored. HMVEC cultured in fully supplemented EGM-2 media (positive control) showed
excellent viability (̰about 85 – 90% live cells) and EdU uptake (roughly 40 - 60% EdU positive cells),
data for EGM condition not shown. BM-MSC CdM generated on DAT coatings increased HMVEC
survival compared to unconditioned media and BM-MSC CdM generated on TCP. Surprisingly, a
significant difference was not observed when supplementing with BM-MSC CdM generated on DAT
microcarriers. This may indicate that culture under static conditions was more instructive for BM-MSC
pro-angiogenic secretory function. However, this effect could also be explained by loss of cells through
shearing off the microcarriers during the conditioning process, as cells may be more sensitive to
detachment under serum-free conditions215. Importantly, CdM collected from an unseeded DAT only
control was significantly lower than BM-MSC-seeded wells, suggesting that residual growth factors or
ECM constituents released from the DAT did not account for the differences seen in HMVEC survival.
Collectively, these data suggest that culture on DAT coatings may alter the secretory function of BMMSC to support endothelial cell survival in vitro.
Previously, MSC CdM has been reported to contain a mixture of pro-angiogenic growth factors including
VEGF, FGF, IGF, HGF, MCP-1, and SDF-1, that supported HMVEC survival, proliferation, and tubule
formation94,97,216. However, our study found no significant differences in HMVEC survival when
supplemented with BM-MSC CdM generated on TCP as previously reported in the literature96,97,216.
Further, no differences were observed in HMVEC proliferation and tubule formation when supplemented
with BM-MSC CdM from the various groups. This lack of response is likely associated with the relatively
low cell numbers used in this study to generate CdM. For comparison, previous groups generated CdM
using 1.6 – 4 million MSC cultured on TCP96,117,195,216,217. In contrast, we generated CdM using 625K
MSC per condition, likely resulting in reduced potency of CdM compared to the other studies. Further,
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previous groups used 50 – 100% CdM supplemented into pro-angiogenic assays with varying
concentrations, while our study used a 10% supplement.
Despite using 3 – 6 x fewer cell numbers and supplementing with smaller concentrations of CdM than
previously reported, BM-MSC cultured on DAT coatings significantly increased HMVEC survival under
serum-free conditions. There may be varying cytokines in the secreted CdM, which may explain why
differences were observed in HMVEC survival while no differences were seen in HMVEC proliferation
or tubule formation. However, it is difficult to predict which cytokines are present in the CdM, as many
growth factors have ubiquitous roles in HMVEC homeostasis and are thus involved in a variety of
interrelated pathways.
The observed pro-survival effects of the generated CdM may be attributed to the ECM composition and
stiffness that can influence MSC behavior. Ogle et al. previously reported enhanced MSC CdM proangiogenic properties when cultured on soft hydrogels, with a Young’s modulus of 30 kPa, containing
integrin and cadherin engaging components145. DAT coatings are similarly soft (~36 kPa)193 while DAT
microcarriers are much softer (~0.73 kPa)120, and DAT contains a wide array of bio-active ECM
constituents that can interact with MSC163,201. The softer composition of DAT microcarriers may also
explain effects seen on BM-MSC CdM, however it is difficult to attribute differences to material stiffness
alone as BM-MSC were also exposed to shear stress on the DAT microcarriers. Overall, the increase in
HMVEC survival following supplementation with CdM from BM-MSC cultured on DAT coatings is
likely due to the biochemical and biomechanical properties of the DAT influencing the BM-MSC
secretome. Similarly, previous work from the Flynn lab showed an angiogenic response from ASC seeded
on DAT bioscaffolds, as CD31+/VEGF+ endothelial cell recruitment was observed into DAT scaffolds
following in vivo implantation175. These findings suggest that DAT scaffolds may provide cell-instructive
cues to increase ASC pro-angiogenic secretory abilities175. Collectively, these findings suggest that DAT
coatings represent a promising culturing platform to generate CdM from BM-MSC that can increase
HMVEC survival under serum-free conditions.
In vivo pro-angiogenic properties of BM-MSC generated under various conditions were also investigated
in a pilot study utilizing the directed in vivo angiogenesis assay (DIVAA™). DIVAA™ inserts were
loaded with basement membrane extract supplemented with CdM from various conditions and
subcutaneously implanted into the flanks of NOD/SCID mice. Following a 14-day period in vivo, inserts
containing CdM from BM-MSC cultured on DAT constructs qualitatively showed increased red blood
cell recruitment compared to TCP culture (Supplementary Figure. 1). However, quantitative analysis did
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not yield statistical significance in lectin uptake by recruited cells. The discrepancy in qualitative and
quantitative data indicated that future optimization is needed to accurately quantify FITC-lectin uptake.
As such, it is difficult to draw conclusions from these in vivo pilot studies. Additionally, angiogenesis is a
complex process that relies on the recruitment of inflammatory cells to orchestrate new blood vessel
formation in vivo45. This study was performed in NOD/SCID mice, with minimal immune cells to guide
angiogenesis in response to pro-angiogenic factors. Future optimization of experiments should explore
implanting CdM-supplemented DIVAA™ inserts in immunocompetent mice to assay for the presence of
lectin uptake by infiltrating endothelial cells, monocytes, and macrophages by quantifying cell surface
marker expression for each cell type using flow cytometry.

4.2.6 DAT Coatings Enriched the Secretome of BM-MSC with Factors Associated with Wound
Healing and ECM remodelling.

To elucidate the composition of collected CdM, global proteomic analysis was performed using label-free
mass spectrometry (MS) for CdM generated under each condition. Lower amounts of proteins were
identified in the dynamic DAT microcarrier CdM group, compared to static culture on TCP or DAT
coatings. Interestingly, this lower secretory breadth correlated with the in vitro studies that showed
minimal effects of DAT Microcarrier CdM on HMVEC survival, proliferation and tubule formation. The
lower number of proteins detected may be attributed to decreased protein secretion under dynamic culture
conditions. However, why this occurred requires further investigation, as reduced protein secretion in
dynamic culture on DAT microcarriers may also be explained by loss of cells though shearing off the
microcarriers during the conditioning process under serum free conditions. Interestingly, principal
component analysis (PCA) revealed tight sample clustering patterns that were culture condition
dependent, indicating that culture of BM-MSC on DAT coatings, TCP, or DAT microcarriers yielded
unique secretory proteomic fingerprints. It should also be noted that greater variability was observed
between MSC from different bone marrow donors cultured on TCP, whereas more clustered analyses
were observed on DAT coatings and DAT microcarriers.
Proteomic analysis identified 18 unique proteins that were upregulated on DAT coatings compared to
TCP, which included fibroblast activation protein (FAP), alpha-1-antitrypsin (SERPINA1),
thrombospondin 4 (THBS4), extracellular sulfatase-1 (SULF1), hepatocyte growth factor-like protein
(MST-1), fibromodulin (FMOD), antithrombin-III (SERPINC1), and contactin-1 (CNTN1). Cross
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referencing these proteins on gene-ontology (GO) Metascape data base revealed they were associated
with wound healing, ECM organization, epithelial cell proliferation, and gland development annotations.
FAP, is a serine-protease that serves important roles that support tumor cell migration and
proliferation218,219. Additionally, when supplemented onto human umbilical vein endothelial cells
(HUVEC), FAP increased cell proliferation rates220. DAT coatings CdM also contained SERPINA1, an
inhibitory enzyme involved in the modulation of acute inflammation by protecting tissues from
inflammatory cell-mediated enzymatic digestion221, further, recombinant SERPINA1 is currently used
clinically for the treatment of lung emphysema222. Another SERPIN was also identified in DAT coating
CdM, SERPINC1, a potent anti-coagulant223 that is also described to possesses anti-angiogenic properties
223,224

. THBS4, is an ECM component that is known to be pro-angiogenic, primarily by inducing ECM

remodelling and inflammatory cell recruitment225,226. Other factors associated with ECM remodelling
were also detected that included FMOD227, likely secreted by MSC in response to the ECM-rich DAT
environment. SULF1, belongs to a family of sulfatases that readily modify the ECM by chemically
altering heparan sulfate proteoglycans in the ECM, thus regulating proteoglycan-cell signalling and
influencing cell survival, growth, and proliferation228,229. MST-1 plays a role in monocyte regulation and
exhibits both pro- and anti-inflammatory effects on macrophages230,231. Additionally, MST-1 is involved
in wound healing through the stimulation of keratinocyte migration in vitro and in mouse wound
models231. Lastly, the cell adhesion molecule232, CNTN1 was also increased in DAT coating CdM and
microcarrier CdM. CNTN1 is expressed by a diversity of neurons and is known to play a role in axonal
development, axon-glia communication, and myelination232–234. These secretome analyses observed an
increase in CNTN1 levels in DAT coatings CdM and DAT microcarriers CdM, at 4.72- and 5.39-fold
increases compare to TCP respectively. Collectively, these findings further warrant the investigation of
BM-MSC on DAT culturing platforms for neuro-regeneration applications. It should further be noted, that
while DAT microcarriers CdM only contained 9 unique proteins compared to TCP, 5 of those were also
upregulated in DAT coatings CdM. Which included FMOD, FAP, SERPINC1, CNTN1, and THBS4.
Indicating that increased release of these factors can be attributed to the DAT substrate independent of
static versus dynamic conditions.
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Chapter 4.3 Clinical Implications
Human DAT is a clinically relevant biomaterial that can be readily obtained from elective lipo-reduction
surgeries, and thus an abundant supply of biomaterial exists for scaling up cell production using both
static or dynamic culture with different DAT substrate formulations163. This study showed the potential of
using DAT constructs to expand BM-MSC while retaining regenerative markers favorable for provascular clinical applications. Our analyses showed that DAT coatings decreased the frequency of nonviable BM-MSC and increased total viable cell counts over time, indicating that culture on DAT coatings
may yield increased BM-MSC numbers by permitting increased surface area, preventing apoptosis and/or
enhancing BM-MSC proliferation. Additionally, prolonged culture on DAT coatings better preserved the
activity of the regenerative and conserved progenitor cell marker, ALDH. Thus, DAT coatings provide an
acceptable alternative to TCP to efficiently expand BM-MSC,
Our studies further observed increases in the frequency of BM-MSC expressing CD271 when the cells
were cultured on DAT microcarriers under dynamic culture. CD271 represents a marker that has been
previously associated with immunomodulatory, angiogenic, and neuroprotective MSC197,198,208,212. Thus,
by retaining ALDH activity and increasing CD271 expression, DAT constructs may be used to expand
MSC while retaining regenerative markers applicable for a variety of therapeutic applications, including
neuro-regeneration applications. Additionally, for blood-vessel regeneration, DAT coatings may enhance
the pro-angiogenic secretome of MSC. Proteomic analyses demonstrated that DAT coatings enhanced the
secretome of BM-MSC with factors associated with wound healing, further supporting future use of DAT
culturing platforms for blood-vessel regeneration applications.
Additionally, the utility of DAT as a potential MSC delivery platform still needs to be addressed. MSC
delivered on DAT coatings or microcarriers may be used to increase MSC survival and retention after
delivery and/or provide a supportive environment that may potentially direct cell function. MSC retention
at the site of injury during clinical translation is predicted to improve the efficacy of MSC-based therapies
by reducing detachment-induced apoptosis.
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Chapter 4.4 Study Limitations and Future Directions
This study attempted to characterize the growth and phenotype of BM-MSC on DAT constructs, however,
some limitations persist regarding how DAT directly influences BM-MSC behavior. Although the viable
yield of BM-MSC was improved when cultured on DAT coatings, it is not clear if there were specific
components within the DAT that contributed to this response. Previous proteomic analysis done by the
Flynn lab identified 804 unique proteins in DAT, of which collagens 1A1, 1A2, and 3A1 were the most
abundant201. As such, it is difficult to predict which component(s) were critical in the responses seen.
Additionally, multiphoton confocal analyses data raised another question, as increased available surface
area was observed between DAT and TCP. Therefore, the question remains whether the DAT is providing
cell-instructive cues to prevent MSC apoptosis or simply provides more surface area available for cell
growth. Further, an increase in total viable MSC counts was observed after culture on DAT coatings,
however, whether this is due to increased proliferation or reduced apoptosis needs to be determined.
Future work should explore the EdU incorporation assay to quantify the frequency of proliferating MSC
on DAT substrates versus TCP.
This study also aimed to characterize cell surface marker expression and regenerative phenotype,
comparing TCP to DAT coatings and DAT microcarriers. We observed no differences in the fraction of
cells expressing the mature stromal markers (CD73, CD90, and CD105) or CD146. However, tri-lineage
differentiation capacity following BM-MSC culture on DAT has yet to be investigated. While previous
work by the Flynn lab showed increased tri-lineage differentiative abilities by ASC following prolonged
culture on DAT microcarriers under dynamic conditions120, this should also be assessed for BM-MSC.
More specifically, future work should investigate differentiation capacity of BM-MSC into fat, bone, and
cartilage following prolonged culture on DAT substrates.
In addition, we observed the retention of high ALDH activity on DAT coatings and an increase in the
frequency of CD271 expression on BM-MSC cultured on DAT microcarriers. Indeed, imaging showed
varying levels of confluency and cell contact between the TCP and DAT conditions, which is known to
influence cell behaviour205,235,236. This is of special importance during DAT microcarrier cultures, as it is
difficult to accurately quantify the surface area available for cell adhesion and growth. Whether the
observed differences in the progenitor markers are due to the instructive properties of the DAT or can be
explained by cell-cell contact mediated cell behaviour requires careful future investigation. Future work
should explore a non-DAT substrate microcarrier/coating control (such as collagen beads/coatings) to
78

elucidate DAT-related effects that are independent of cell density. Overall, it is difficult to draw a direct
comparison between DAT coatings and DAT microcarriers as many differences exist in the culture
platforms such as stiffness, cell density, and shear stresses. As such it can be difficult to uncouple which
parameter had the greatest effect on the observed responses.
In terms of the increase in the neutrotrophin receptor CD271 on BM-MSC following culture on DAT
microcarriers. Future work should perform functional neural survival/proliferation assays to elucidate the
presence of neutrotrophins in BM-MSC CdM. Furthermore, the use of DAT microcarriers with BM-MSC
for neuro-regeneration should be further explored in mouse models.
In this study the pro-angiogenic signalling of BM-MSC was assessed by collecting CdM and assaying for
HMVEC survival, proliferation, and tubule formation. Although differences in HMVEC survival were
observed when the media was supplemented with DAT coatings CdM compared to other groups, we did
not observe differences in cell proliferation or tubule formation as previously reported in the
literature96,97,216. As discussed previously, this may be due to the lower cell numbers used in this study
(625K), and future work should collect CdM from 2 – 4 million BM-MSC similar to the cell numbers
used to generate CdM in previous studies97,144,195. In addition, supplementation of HMVEC cultures was
limited to 10% CdM, and future experiments should supplement with previously reported concentrations
that range from 50 – 100% CdM supplements96,97,195.
Additionally, to obtain a more pro-angiogenic secretome from BM-MSC, future work should condition
BM-MSC under hypoxia as a stressor to stimulate the release of pro-angiogenic factors. It was previously
shown that MSC or ASC cultured under hypoxia (1 - 3% oxygen) exhibited a more pro-angiogenic
secretory profile than those cultured under normoxic (20 - 21% oxygen) conditions237–239. Although BMMSC in this study were exposed to serum- and growth factor-free cultures during conditioning, culture
under atmospheric oxygen tension would not be expected to stimulate the secretion of potent proangiogenic effectors that are stimulated by the actions of the HIF-1α-hypoxia signalling axis52.
It should also be noted that while CD271 and ALDH-activity have been associated with regenerative
phenotypes in MSC72,195–198,203, it is difficult to draw conclusions about cell behaviour without performing
additional functional assays. This study lacked a complete in vivo characterization of pro-angiogenic
stimulatory properties of BM-MSC on DAT constructs. This is crucial as proteomic analyses detected
factors that are supportive of angiogenesis such as SERPINA1, THSB4, MST-1, and FAP, however many
of these factors exhibit a pro-angiogenic response through inflammatory cell modulation, ECM79

remodelling, and/or modulating coagulation220,222,226,231, all mechanism that could only be fully detected in
vivo. This warrants future investigations to involve direct injections of BM-MSC CdM into
immunocompetent mice. In this project, the DIVAA™ assay was performed to quantify endothelial cell
infiltration following supplementation with CdM, however quantification of this experiment requires
future optimization and further repeats. Future work could also assess alternative markers to quantify
immune cell infiltration into inserts in immunocompetent mice, to detect potential activity by FAP, MST,
and/or SERPINA1. Macrophage & monocyte infiltration maybe quantified by measuring lectin uptake
alongside CD14, CD11b, or CD144 expression240,241 by flow cytometry. Future work should also utilize
an applicable in vivo model of ischemia such as the femoral artery ligation (FAL)-induced limb
ischemia72. Subsequently, CdM generated by MSC could be injected into the ischemic limb of mice that
have underwent FAL, and laser doppler imaging, the CatWalk™ assay, and immunohistochemistry (IHC)
could be used to quantify limb perfusion, functional limb use, and new capillary formation, respectively.
Proteomic analyses also revealed an interesting observation regarding total quantified proteins in the DAT
microcarriers CdM, as lower numbers of unique peptides were detected. This may be due to a decreased
secretome when BM-MSC are cultured under dynamic conditions. However, as previously discussed, the
lower protein amounts may be explained by loss of cells that could be more sensitive to the shear forces
applied within the spinner flasks following conditioning in serum-free culture. Future work should
include imaging of the seeded DAT microcarriers before and after conditioning to observe whether there
are any issues with cell detachment.
Finally, the utility of DAT microcarriers as a delivery vector should be fully explored using the FALmouse model, where BM-MSC adherent on DAT microcarriers could be subcutaneously delivered into to
the ischemic limb and human cell retention would be quantified using IHC. Collectively, these additional
assessments with the work uncovered in this thesis will help elucidate MSC function within DAT
constructs, and characterize the potential for blood-vessel regeneration applications.
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Chapter 4.5 Conclusions
This novel multidisciplinary study aimed to improve the expansion and therapeutic potential of BM-MSC
using an extracellular matrix-rich scaffold derived from DAT. DAT provided a robust cell-supportive
environment that promoted BM-MSC attachment and growth while retaining regenerative markers.
Culture on DAT coatings under static conditions maintained the fraction of BM-MSC expressing the
conserved progenitor marker ALDH-activity, while culture on DAT microcarriers under dynamic
conditions increased the frequency of cells expressing the potentially regenerative marker, CD271. These
findings suggest that DAT constructs may be used to expand BM-MSC suitable for a variety of
therapeutic applications. Further, BM-MSC cultured on DAT coatings generated CdM that increased the
survival of endothelial cells under serum-free conditions. Lastly, culture of BM-MSC on DAT coatings
resulted in a secretome that contained factors associated with wound healing. Overall, these studies
support the further investigation of DAT constructs as a cell expansion platform for BM-MSC, which
may have future potential for blood vessel regeneration applications.
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Appendices
Appendix. 1 Supplementary Figures
Directed In Vivo Angiogenesis Assay™:
The ability of BM-MSC CdM to induce an angiogenic response in vivo was assessed in a preliminary
study using the directed in vivo angiogenesis assay (DIVAATM). DIVAA™ inserts were loaded with
basement membrane extract supplemented with BM-MSC CdM generated under the various culture
conditions and subcutaneously implanted into the flanks of NOD/SCID mice. After 14 days in vivo inserts
were retrieved and imaged. Inserts containing CdM from BM-MSC cultured on DAT constructs
qualitatively showed higher infiltration of red blood cells compared to TCP CdM (Figure 3.9A). To
quantify endothelial cell infiltration into DIVAATM angioreactors, DIVAATM inserts were digested and
infiltrating endothelial cells were stained with FITC-Lectin and quantified using a fluorescent plate
reader. Surprisingly, there were no significant differences in FITC-Lectin uptake in DIVAATM inserts
when supplemented with CdM from BM-MSC cultured on the various substrates (Figure 3.9B).
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A

B

Supplementary figure 1. Preliminary analyses of cell infiltration into DIVAA™ inserts
containing BM-MSC CdM. DIVAA™ inserts loaded with BM-MSC CdM generated under the
various culture conditions were retrieved 14 days after subcutaneous implantation in NOD/SCID
mice. Endothelial cell infiltration was quantified using lectin-FITC uptake. (A) Representative
images of retrieved DIVAA™ inserts at 14 days post-implantation, with apparent red blood cell
infiltration observed in the BM-MSC CdM groups and growth factor-supplemented positive
controls. (B) Surprisingly, no significant differences in EC infiltration into DIVAATM inserts were
detected when supplemented with BM-MSC CdM generated under the various culture conditions.
Data represents Mean ± SD, showing CdM from three different BM donors (N=3, n=3-9). Analysis
for statistical significance was performed using a one-way ANOVA followed by Tukey’s post hoc
multiple comparisons test. Quantitative analysis requires future optimizations.
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